CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | anti-ulcer drug |
|
Accession: | CHEBI:49201
|
browse the term
|
Definition: | One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. |
Synonyms: | related_synonym: | anti-ulcer agent; anti-ulcer agents; anti-ulcer drugs |
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15578100 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance affects localization |
ISO |
BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2 16,16-Dimethylprostaglandin E2 affects the localization of BAX protein |
CTD |
PMID:15578100 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:15578100 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases activity |
ISO |
16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein |
CTD |
PMID:14736730 |
|
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:11686837 PMID:11855677 PMID:11991626 PMID:18306037 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] |
CTD |
PMID:11686837 PMID:11855677 PMID:11991626 PMID:15610444 PMID:18306037 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA] 16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:9099957 PMID:15610444 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] |
CTD |
PMID:9298541 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
EXP |
5-hydroxymethylomeprazole results in increased expression of CYP1A1 protein |
CTD |
PMID:10103034 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of BAX protein] amlexanox results in decreased expression of BAX protein |
CTD |
PMID:31697998 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] |
CTD |
PMID:31697998 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CCL2 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CXCL2 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of CXCL1 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
ISO |
[amlexanox binds to FGF1 protein] inhibits the reaction [cupric chloride results in increased oxidation of FGF1 protein]; amlexanox binds to and results in increased stability of and results in decreased secretion of FGF1 protein; amlexanox inhibits the reaction [FGF1 protein binds to FGF1 protein] |
CTD |
PMID:16300395 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[Acetaminophen co-treated with amlexanox co-treated with dorsomorphin] affects the expression of GCLC mRNA; [Acetaminophen co-treated with amlexanox] affects the expression of GCLC mRNA amlexanox results in increased expression of GCLC mRNA |
CTD |
PMID:31697998 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Acetaminophen co-treated with amlexanox co-treated with dorsomorphin] affects the expression of GCLM mRNA |
CTD |
PMID:31697998 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of GPT protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in increased expression of GPT protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects localization |
ISO |
amlexanox affects the localization of GPX1 mRNA mutant form |
CTD |
PMID:28743738 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[amlexanox co-treated with Acetaminophen] results in increased expression of HMOX1 mRNA; amlexanox promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; dorsomorphin inhibits the reaction [[amlexanox co-treated with Acetaminophen] results in increased expression of HMOX1 mRNA] amlexanox results in increased expression of HMOX1 mRNA |
CTD |
PMID:31697998 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
decreases activity multiple interactions |
ISO |
amlexanox results in decreased activity of IKBKE protein amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of IKBKE protein] |
CTD |
PMID:25321315 PMID:31697998 |
|
NCBI chr13:48,031,325...48,056,394
Ensembl chr13:48,031,410...48,056,394
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of IL1B mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of IL6 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression multiple interactions |
ISO |
amlexanox results in increased expression of NFE2L2 protein [Acetaminophen co-treated with amlexanox] results in increased expression of NFE2L2 protein; amlexanox inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
dorsomorphin inhibits the reaction [[Acetaminophen co-treated with amlexanox] affects the expression of NQO1 mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation multiple interactions |
ISO |
amlexanox results in increased phosphorylation of PRKAA1 protein [Acetaminophen co-treated with amlexanox] results in increased phosphorylation of PRKAA1 protein; amlexanox inhibits the reaction [Acetaminophen results in decreased phosphorylation of PRKAA1 protein]; dorsomorphin inhibits the reaction [amlexanox inhibits the reaction [Acetaminophen results in decreased phosphorylation of PRKAA1 protein]] |
CTD |
PMID:31697998 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of RELA protein] |
CTD |
PMID:31697998 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
decreases activity decreases phosphorylation multiple interactions |
ISO |
amlexanox results in decreased activity of TBK1 protein amlexanox results in decreased phosphorylation of TBK1 protein amlexanox inhibits the reaction [Acetaminophen results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25321315 PMID:31697998 |
|
NCBI chr 7:63,655,247...63,687,978
Ensembl chr 7:63,655,247...63,687,978
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
amlexanox inhibits the reaction [Acetaminophen results in increased expression of TNF mRNA] |
CTD |
PMID:31697998 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Upf1 |
UPF1, RNA helicase and ATPase |
affects localization |
ISO |
amlexanox affects the localization of UPF1 protein |
CTD |
PMID:28743738 |
|
NCBI chr16:20,824,888...20,845,632
Ensembl chr16:20,824,864...20,845,243
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA] Artesunate results in decreased expression of ACTA2 mRNA; Artesunate results in decreased expression of ACTA2 protein Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:30551460 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization |
ISO |
artesunate affects the localization of AIFM1 protein |
CTD |
PMID:24704559 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
artesunate binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
ISO |
Artesunate results in increased expression of ATG12 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126
|
|
G |
Atg3 |
autophagy related 3 |
increases expression |
ISO |
Artesunate results in increased expression of ATG3 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr11:60,585,192...60,613,706
Ensembl chr11:60,585,171...60,613,718
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Artesunate results in increased expression of ATG5 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
artesunate results in increased expression of BAX protein [1,2-Dimethylhydrazine co-treated with artesunate] results in increased expression of BAX protein |
CTD |
PMID:24704559 PMID:29031619 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
artesunate results in decreased expression of BCL2 protein [1,2-Dimethylhydrazine co-treated with artesunate] results in decreased expression of BCL2 protein |
CTD |
PMID:24704559 PMID:29031619 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
increases response to substance |
ISO |
BST1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr14:71,798,218...71,814,540
Ensembl chr14:71,798,651...71,814,523
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
artesunate results in increased activity of CASP3 protein |
CTD |
PMID:19513562 PMID:24704559 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
affects expression |
ISO |
artesunate affects the expression of CASP9 protein |
CTD |
PMID:24704559 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
increases expression decreases response to substance |
ISO |
artesunate results in increased expression of CAT protein CAT protein results in decreased susceptibility to artesunate |
CTD |
PMID:19513562 PMID:20144594 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
decreases response to substance |
ISO |
CCT2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:60,106,532...60,122,779
Ensembl chr 7:60,109,974...60,122,805
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation |
ISO |
APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK1 protein] |
CTD |
PMID:31664825 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases phosphorylation |
ISO |
APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:31664825 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases response to substance |
ISO |
CLIP4 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 6:23,222,020...23,316,962
Ensembl chr 6:23,222,021...23,316,962
|
|
G |
Coq8a |
coenzyme Q8A |
decreases response to substance |
ISO |
COQ8A mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr13:98,451,629...98,480,438
Ensembl chr13:98,451,637...98,480,419
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CTNNB1 protein] |
CTD |
PMID:29031619 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Dbh |
dopamine beta-hydroxylase |
increases response to substance |
ISO |
DBH mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
|
|
G |
Des |
desmin |
multiple interactions decreases expression |
ISO |
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA] Artesunate results in decreased expression of DES mRNA; Artesunate results in decreased expression of DES protein |
CTD |
PMID:30551460 |
|
NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
artesunate binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
artesunate results in increased expression of FAS protein |
CTD |
PMID:19513562 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Flna |
filamin A |
increases response to substance |
ISO |
FLNA mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr X:156,460,785...156,487,245
Ensembl chr X:156,463,953...156,487,245
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions decreases expression |
ISO |
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA] Artesunate results in decreased expression of FN1 mRNA; Artesunate results in decreased expression of FN1 protein |
CTD |
PMID:30551460 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fth1 |
ferritin heavy chain 1 |
decreases expression multiple interactions |
ISO |
Artesunate results in decreased expression of FTH1 mRNA; Artesunate results in decreased expression of FTH1 protein Chloroquine inhibits the reaction [Artesunate results in decreased expression of FTH1 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Fzd7 |
frizzled class receptor 7 |
increases response to substance |
ISO |
FZD7 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects response to substance decreases response to substance |
ISO |
GCLC mRNA affects the susceptibility to artesunate GCLC mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases response to substance |
ISO |
GCLM mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases activity multiple interactions |
ISO |
Artesunate results in decreased activity of GPX4 protein Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of GPX4 protein] |
CTD |
PMID:30551460 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
affects response to substance |
ISO |
GSTM4 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 2:210,834,013...210,839,242
Ensembl chr 2:210,833,884...210,839,295
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
artesunate results in decreased expression of GSTP1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
affects response to substance |
ISO |
GSTT2 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr20:13,760,810...13,764,481
Ensembl chr20:13,760,810...13,764,475
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects response to substance |
ISO |
GSTZ1 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Artesunate inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL1B protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Artesunate inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL6 protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases response to substance |
ISO |
ITGB1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
affects response to substance |
ISO |
MGST3 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr13:85,601,499...85,622,392
Ensembl chr13:85,601,499...85,622,314
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein] |
CTD |
PMID:29031619 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MMP9 protein] Chloroquine inhibits the reaction [Artesunate results in decreased expression of MMP9 mRNA] |
CTD |
PMID:29031619 PMID:30551460 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:27474069 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases response to substance |
ISO |
MTHFD2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of MYD88 protein] |
CTD |
PMID:30031708 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Naca |
nascent polypeptide associated complex subunit alpha |
decreases response to substance |
ISO |
NACA mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:2,458,283...2,470,674
Ensembl chr 7:2,458,264...2,470,674
|
|
G |
Nckap1 |
NCK-associated protein 1 |
increases response to substance |
ISO |
NCKAP1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 3:67,725,180...67,804,680
Ensembl chr 3:67,725,947...67,787,990
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of NCOA4 mRNA] Artesunate results in decreased expression of NCOA4 mRNA; Artesunate results in decreased expression of NCOA4 protein |
CTD |
PMID:30551460 |
|
NCBI chr16:8,302,950...8,323,294
Ensembl chr16:8,302,950...8,323,293
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
artesunate affects the localization of NFE2L2 protein |
CTD |
PMID:26340163 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of NLRP3 protein] |
CTD |
PMID:30031708 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
artesunate results in increased cleavage of PARP1 protein |
CTD |
PMID:24704559 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] |
CTD |
PMID:29031619 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
artesunate binds to and results in increased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 mRNA; [Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 protein |
CTD |
PMID:30551460 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased expression of RELA protein]; artesunate inhibits the reaction [Glucose results in increased phosphorylation of RELA protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rpa2 |
replication protein A2 |
increases phosphorylation |
ISO |
Artesunate results in increased phosphorylation of RPA2 protein |
CTD |
PMID:31664825 |
|
NCBI chr 5:150,957,041...150,967,597
Ensembl chr 5:150,957,001...150,968,269
|
|
G |
Rpl41 |
ribosomal protein L41 |
decreases response to substance |
ISO |
RPL41 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:2,972,897...2,973,977
Ensembl chr 7:2,972,900...2,973,977
|
|
G |
Rpl6 |
ribosomal protein L6 |
decreases response to substance |
ISO |
RPL6 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr12:40,877,578...40,882,032
Ensembl chr12:40,877,613...40,881,124
|
|
G |
Rpl7 |
ribosomal protein L7 |
decreases response to substance |
ISO |
RPL7 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 5:2,633,517...2,636,525
Ensembl chr 5:2,632,712...2,640,021
|
|
G |
Rps12 |
ribosomal protein S12 |
decreases response to substance |
ISO |
RPS12 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:22,758,214...22,760,370
Ensembl chr 1:22,758,212...22,760,370
|
|
G |
Rps15a |
ribosomal protein S15a |
decreases response to substance |
ISO |
RPS15A mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:187,759,865...187,766,734
Ensembl chr 1:187,759,480...187,766,709
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases response to substance |
ISO |
RPS6 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
decreases response to substance |
ISO |
SLC25A19 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:104,166,594...104,179,523
Ensembl chr10:104,166,598...104,179,523
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression |
ISO |
artesunate results in decreased expression of SP1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of SQSTM1 protein] Artesunate results in decreased expression of SQSTM1 mRNA; Artesunate results in decreased expression of SQSTM1 protein |
CTD |
PMID:30551460 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srsf2 |
serine and arginine rich splicing factor 2 |
decreases response to substance |
ISO |
SRSF2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:105,792,779...105,795,986
Ensembl chr10:105,792,779...105,795,958
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Artesunate results in increased expression of TIMP1 mRNA Chloroquine inhibits the reaction [Artesunate results in increased expression of TIMP1 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of TLR4 protein] |
CTD |
PMID:30031708 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased expression of TNF protein]; artesunate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; artesunate inhibits the reaction [Glucose results in increased secretion of TNF protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
affects response to substance |
ISO |
TPT1 protein affects the susceptibility to artesunate |
CTD |
PMID:15878303 |
|
NCBI chr15:57,891,680...57,894,504
Ensembl chr15:57,891,680...57,894,504
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases response to substance |
ISO |
TUFM mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:197,903,582...197,907,189
Ensembl chr 1:197,903,582...197,907,189
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of VEGFA protein] |
CTD |
PMID:29031619 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Yy1 |
YY1 transcription factor |
decreases expression |
ISO |
artesunate results in decreased expression of YY1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 6:132,702,443...132,726,848
Ensembl chr 6:132,702,448...132,727,046
|
|
G |
Zbtb4 |
zinc finger and BTB domain containing 4 |
increases response to substance |
ISO |
ZBTB4 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:56,367,586...56,388,296
Ensembl chr10:56,381,813...56,385,960
|
|
|
G |
Mpo |
myeloperoxidase |
decreases activity |
ISO |
balsalazide results in decreased activity of MPO protein |
CTD |
PMID:19296261 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport multiple interactions |
ISO |
ABCG2 protein affects the transport of Cimetidine Cimetidine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride] |
CTD |
PMID:15365089 PMID:15722455 PMID:26907376 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH1C protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH4 protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:243,702,035...243,720,063
Ensembl chr 2:243,700,784...243,740,899
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH5 protein results in increased oxidation of S-hydroxymethylglutathione] |
CTD |
PMID:23220590 |
|
NCBI chr 2:243,728,500...243,740,907
Ensembl chr 2:243,700,784...243,740,899
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ADH7 protein results in increased oxidation of Ethanol] |
CTD |
PMID:23220590 |
|
NCBI chr 2:243,500,540...243,516,865
Ensembl chr 2:243,502,073...243,516,532
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Cimetidine promotes the reaction [Metformin results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:20956498 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects expression multiple interactions |
ISO |
Cimetidine affects the expression of AHR protein [Monocrotophos co-treated with Cimetidine] results in increased expression of AHR protein |
CTD |
PMID:22733800 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ALDH1A1 protein results in increased oxidation of Acetaldehyde] |
CTD |
PMID:23220590 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [ALDH3A1 protein results in increased oxidation of benzaldehyde] |
CTD |
PMID:23220590 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases activity |
ISO |
Cimetidine results in increased activity of APAF1 protein |
CTD |
PMID:17273750 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression |
ISO EXP |
Cimetidine inhibits the reaction [Dihydrotestosterone binds to AR protein] Cimetidine results in decreased expression of AR protein |
CTD |
PMID:6835285 PMID:26021711 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Cimetidine results in increased expression of BAX protein Cimetidine inhibits the reaction [Ethanol results in increased expression of BAX protein] |
CTD |
PMID:20127008 PMID:27983966 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of BCL2 protein Cimetidine inhibits the reaction [Ethanol results in decreased expression of BCL2 protein] |
CTD |
PMID:20127008 PMID:27983966 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
ISO |
Cimetidine results in increased activity of CASP1 protein CASP1 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] |
CTD |
PMID:16723495 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of CASP12 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases expression |
ISO EXP |
Cimetidine results in increased activity of CASP3 protein Cimetidine inhibits the reaction [Ethanol results in increased expression of CASP3 protein] Cimetidine results in increased expression of CASP3 protein |
CTD |
PMID:17273750 PMID:20127008 PMID:26021711 PMID:27983966 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP7 protein |
CTD |
PMID:17273750 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP8 protein |
CTD |
PMID:17273750 PMID:20127008 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Cimetidine results in increased activity of CASP9 protein |
CTD |
PMID:17273750 PMID:20127008 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 protein] |
CTD |
PMID:12107048 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Cimetidine results in decreased expression of CD14 protein |
CTD |
PMID:11556524 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Cisplatin results in increased expression of CST3] |
CTD |
PMID:22525860 |
|
NCBI chr 3:143,219,671...143,223,544
Ensembl chr 3:143,219,686...143,223,615
|
|
G |
Ctsd |
cathepsin D |
decreases activity |
EXP |
Cimetidine results in decreased activity of CTSD protein |
CTD |
PMID:12903910 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctsl |
cathepsin L |
decreases activity |
EXP |
Cimetidine results in decreased activity of CTSL protein |
CTD |
PMID:12903910 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
ISO |
Cimetidine inhibits the reaction [Cocaine results in increased expression of CYP1A1 protein] Cimetidine results in decreased expression of CYP1A1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP1A1 protein Cimetidine results in decreased activity of CYP1A1 protein |
CTD |
PMID:11856816 PMID:22733800 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP1A2 protein] |
CTD |
PMID:7946932 PMID:19909766 PMID:31863871 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression multiple interactions decreases activity |
ISO |
Cimetidine results in decreased expression of CYP2B6 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP2B6 protein Cimetidine results in decreased activity of CYP2B6 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
Cimetidine inhibits the reaction [CYP2C11 protein results in increased glutathionylation of lamotrigine] |
CTD |
PMID:19961160 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity multiple interactions |
ISO EXP |
Cimetidine results in decreased activity of CYP2D6 protein Cimetidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan] styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP2D6 protein] |
CTD |
PMID:17651725 PMID:19909766 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of CYP2E1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP2E1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Cocaine results in increased expression of CYP2J2 protein] |
CTD |
PMID:11856816 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases expression multiple interactions decreases activity |
ISO |
Cimetidine results in decreased expression of CYP3A4 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of CYP3A4 protein; Cimetidine inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Nifedipine]; styrofoam analog promotes the reaction [Cimetidine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:2271712 PMID:16041596 PMID:18846481 PMID:19909766 PMID:22733800 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] [Cimetidine results in decreased abundance of Cyclic AMP] inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:17295779 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
affects expression |
ISO |
Cimetidine affects the expression of FSHB protein |
CTD |
PMID:435711 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Gast |
gastrin |
affects expression |
ISO |
Cimetidine affects the expression of GAST protein |
CTD |
PMID:12503773 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects expression multiple interactions |
ISO |
Cimetidine affects the expression of GSTP1 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of GSTP1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in increased expression of HMOX1 protein] |
CTD |
PMID:12806184 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [HRH1 results in decreased susceptibility to Morphine] |
CTD |
PMID:14569158 |
|
NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity increases expression |
ISO EXP |
[Cimetidine binds to and results in decreased activity of HRH2 protein] results in decreased susceptibility to [Histamine co-treated with [Oxygen deficiency co-treated with Oxygen]]; [Cimetidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Cimetidine binds to and results in decreased activity of HRH2 protein; Cimetidine binds to and results in increased activity of HRH2 protein; Cimetidine inhibits the reaction [HRH2 protein promotes the reaction [Histamine results in increased expression of IL16 protein]] Cimetidine results in decreased activity of HRH2 protein [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased susceptibility to clobenpropit; Cimetidine binds to and results in decreased activity of HRH2 protein; Cimetidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine] Cimetidine binds to and results in increased activity of HRH2 protein; Cimetidine inhibits the reaction [HRH2 results in decreased susceptibility to Morphine]; HRH2 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] Cimetidine results in increased expression of HRH2 protein |
CTD |
PMID:1912125 PMID:2461127 PMID:6522242 PMID:9681472 PMID:12235264 PMID:14569158 PMID:15961859 PMID:16488453 PMID:16632449 PMID:16723495 PMID:19215234 PMID:21276809 PMID:22926047 |
|
NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:27983966 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of ICAM1 protein |
CTD |
PMID:17189874 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO |
Cimetidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of IFNG protein]] Cimetidine results in increased expression of IFNG mRNA; Cimetidine results in increased expression of IFNG protein |
CTD |
PMID:10569698 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [HRH2 protein promotes the reaction [Histamine results in increased expression of IL16 protein]] |
CTD |
PMID:12235264 |
|
NCBI chr 1:145,781,923...145,881,538
Ensembl chr 1:145,781,928...145,870,912
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases expression |
ISO |
CASP1 protein affects the reaction [Cimetidine results in increased expression of IL18 protein]; Famotidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Ranitidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein] HRH2 protein affects the reaction [Cimetidine results in increased expression of IL18 protein] |
CTD |
PMID:16723495 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:12065299 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Itga4 |
integrin subunit alpha 4 |
decreases expression |
ISO |
Cimetidine results in decreased expression of ITGA4 protein |
CTD |
PMID:11556524 |
|
NCBI chr 3:66,178,745...66,265,547
Ensembl chr 3:66,193,059...66,263,960
|
|
G |
Itgax |
integrin subunit alpha X |
decreases expression |
ISO |
Cimetidine results in decreased expression of ITGAX protein |
CTD |
PMID:11556524 |
|
NCBI chr 1:199,555,560...199,576,948
Ensembl chr 1:199,555,722...199,576,932
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of LRP1 protein |
CTD |
PMID:11556524 |
|
NCBI chr 7:70,846,313...70,927,028
Ensembl chr 7:70,846,344...70,926,903
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases expression |
ISO |
Cimetidine results in decreased expression of NCAM mRNA; Cimetidine results in decreased expression of NCAM protein |
CTD |
PMID:17273750 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of NFKB1 protein] |
CTD |
PMID:12065299 PMID:12107048 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of NR1I2 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of NR1I2 protein |
CTD |
PMID:22733800 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases expression multiple interactions |
ISO |
Cimetidine results in decreased expression of NR1I3 protein [Monocrotophos co-treated with Cimetidine] results in increased expression of NR1I3 protein |
CTD |
PMID:22733800 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
Cimetidine inhibits the reaction [Histamine results in increased expression of NTF3 protein] |
CTD |
PMID:21276809 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Histamine results in increased expression of PDE4B mRNA] |
CTD |
PMID:11131300 |
|
NCBI chr 5:121,759,236...122,136,814
Ensembl chr 5:121,952,977...122,136,814
|
|
G |
Prl |
prolactin |
affects expression |
ISO |
Cimetidine affects the expression of PRL protein |
CTD |
PMID:435711 PMID:9037573 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prok1 |
prokineticin 1 |
decreases expression |
EXP |
Cimetidine results in decreased expression of PROK1 protein |
CTD |
PMID:26021711 |
|
NCBI chr 2:209,986,503...209,994,438
Ensembl chr 2:209,987,992...209,993,250
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; Cimetidine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of and results in increased activity of RELA protein] Cimetidine inhibits the reaction [Ethanol results in increased expression of RELA protein] |
CTD |
PMID:12065299 PMID:12107048 PMID:24300194 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Selp |
selectin P |
decreases expression |
ISO |
Cimetidine results in decreased expression of SELP protein |
CTD |
PMID:17189874 |
|
NCBI chr13:82,428,914...82,464,629
Ensembl chr13:82,429,063...82,464,628
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases uptake multiple interactions |
EXP ISO |
SLC22A1 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium] |
CTD |
PMID:16006492 PMID:19357179 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions increases transport decreases response to substance increases uptake |
ISO EXP |
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine]; Cimetidine inhibits the reaction [SLC22A2 protein affects the transport of Tetraethylammonium]; Cimetidine inhibits the reaction [SLC22A2 protein polymorphism results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium]; p-Aminohippuric Acid inhibits the reaction [SLC22A2 protein results in increased uptake of Cimetidine] SLC22A2 protein results in increased transport of Cimetidine SLC22A2 gene polymorphism results in decreased susceptibility to Cimetidine |
CTD |
PMID:15496291 PMID:16006492 PMID:18230276 PMID:19357179 PMID:21599003 PMID:22525860 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions increases transport |
ISO |
Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium]; Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin] Cimetidine inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] SLC22A3 protein results in increased transport of Cimetidine |
CTD |
PMID:10966924 PMID:18253050 PMID:19357179 PMID:21697722 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions increases uptake |
ISO |
1-Methyl-4-phenylpyridinium inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine]; Cimetidine inhibits the reaction [SLC22A6 protein affects the transport of p-Aminohippuric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Cimetidine] |
CTD |
PMID:15496291 PMID:16006492 PMID:16098483 |
|
NCBI chr 1:224,824,809...224,833,284
Ensembl chr 1:224,824,799...224,833,259
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases uptake multiple interactions |
ISO |
SLC22A7 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 PMID:16006492 |
|
NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake affects transport |
ISO EXP |
Cimetidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Cimetidine] SLC22A8 protein results in increased uptake of Cimetidine Cimetidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] estradiol-17 beta-glucuronide inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; p-Aminohippuric Acid inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Cimetidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Ranitidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine] |
CTD |
PMID:10224140 PMID:11306713 PMID:15100168 PMID:15319347 PMID:15496291 PMID:16006492 PMID:16098483 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
affects transport multiple interactions decreases activity |
ISO |
SLC47A1 protein affects the transport of Cimetidine Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of Cadmium] Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC47A1 protein results in increased uptake of Cadmium] Cimetidine results in decreased activity of SLC47A1 protein |
CTD |
PMID:16928787 PMID:21599003 PMID:27871888 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [SLC47A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Cimetidine inhibits the reaction [SLC47A2 protein results in increased uptake of Cadmium] |
CTD |
PMID:21599003 PMID:27871888 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
multiple interactions |
EXP |
[piperine co-treated with Cimetidine co-treated with Pyruvates] inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of SLC9A3 protein] |
CTD |
PMID:12806184 |
|
NCBI chr 1:31,731,652...31,777,144
Ensembl chr 1:31,734,327...31,777,070
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Cimetidine inhibits the reaction [Dimaprit inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Cimetidine inhibits the reaction [Cocaine results in increased expression of TNF protein] |
CTD |
PMID:9088875 PMID:11856816 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Cisapride results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr 8:23,142,733...23,149,067
Ensembl chr 8:23,142,734...23,148,396
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr 2:196,655,469...196,666,447
Ensembl chr 2:196,655,469...196,666,446
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects metabolic processing affects chemical synthesis multiple interactions decreases activity |
ISO |
CYP3A4 protein affects the metabolism of Cisapride CYP3A4 protein affects the chemical synthesis of Cisapride metabolite Cisapride inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] Cisapride results in decreased activity of CYP3A4 protein |
CTD |
PMID:11717173 PMID:15306208 PMID:19299527 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr 7:78,642,016...78,651,763
Ensembl chr 7:78,649,875...78,650,906
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects localization affects binding |
ISO |
beta-Cyclodextrins analog inhibits the reaction [Cisapride results in decreased activity of KCNH2 protein]; Cisapride binds to and results in decreased activity of KCNH2 protein; Cisapride inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Cisapride affects the localization of KCNH2 protein mutant form Cisapride binds to KCNH2 protein |
CTD |
PMID:9395068 PMID:10531299 PMID:11005845 PMID:11741928 PMID:12388285 PMID:15272206 PMID:15306208 PMID:15671647 PMID:15740727 PMID:17513944 PMID:18701618 PMID:19260734 PMID:19583963 PMID:21158687 PMID:24052561 PMID:24830940 PMID:27553911 PMID:28551711 PMID:30561737 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr18:77,203,517...77,322,690
Ensembl chr18:77,203,525...77,322,690
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
increases localization |
ISO |
Cisapride results in increased localization of SCN5A protein mutant form |
CTD |
PMID:16301357 |
|
NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Cisapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Cisapride inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:31150804 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
affects expression |
ISO |
diethyl malate affects the expression of ACTA2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actc1 |
actin, alpha, cardiac muscle 1 |
affects expression |
ISO |
diethyl malate affects the expression of ACTC1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:105,507,403...105,512,939
Ensembl chr 3:105,507,403...105,512,939
|
|
G |
Actn3 |
actinin alpha 3 |
affects expression |
ISO |
diethyl malate affects the expression of ACTN3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:220,120,532...220,136,460
Ensembl chr 1:220,120,533...220,136,470
|
|
G |
Adcy1 |
adenylate cyclase 1 |
affects expression |
ISO |
diethyl malate affects the expression of ADCY1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr14:87,311,970...87,429,880
Ensembl chr14:87,312,203...87,421,659
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
affects expression |
ISO |
diethyl malate affects the expression of ADH1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Agt |
angiotensinogen |
affects expression |
ISO |
diethyl malate affects the expression of AGT mRNA |
CTD |
PMID:24814887 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
C3 |
complement C3 |
affects expression |
ISO |
diethyl malate affects the expression of C3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
affects expression |
ISO |
diethyl malate affects the expression of CACNB2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
|
|
G |
Cacnb4 |
calcium voltage-gated channel auxiliary subunit beta 4 |
affects expression |
ISO |
diethyl malate affects the expression of CACNB4 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:37,950,846...38,211,478
Ensembl chr 3:37,955,069...38,090,526
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions affects expression |
ISO |
S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of CAMK2A mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
affects expression |
ISO |
diethyl malate affects the expression of CCL20 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
affects expression |
ISO |
diethyl malate affects the expression of CCL6 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
affects expression |
ISO |
diethyl malate affects the expression of CCL7 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:69,423,083...69,424,933
Ensembl chr10:69,423,086...69,424,979
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
affects expression |
ISO |
diethyl malate affects the expression of COL11A1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:216,863,423...217,056,523
Ensembl chr 2:216,863,428...217,056,523
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
affects expression |
ISO |
diethyl malate affects the expression of COL2A1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
affects expression |
ISO |
diethyl malate affects the expression of COL3A1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
affects expression |
ISO |
diethyl malate affects the expression of COL6A1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr20:12,657,913...12,676,370
Ensembl chr20:12,658,065...12,675,561
|
|
G |
Comp |
cartilage oligomeric matrix protein |
affects expression |
ISO |
diethyl malate affects the expression of COMP mRNA |
CTD |
PMID:24814887 |
|
NCBI chr16:20,798,437...20,807,070
Ensembl chr16:20,798,437...20,807,070
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
affects expression multiple interactions |
ISO |
diethyl malate affects the expression of CXCL12 mRNA S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of CXCL12 mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
affects expression |
ISO |
diethyl malate affects the expression of CXCL1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
affects expression |
ISO |
diethyl malate affects the expression of CXCL5 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr14:18,860,201...18,920,839
Ensembl chr14:18,860,264...18,862,407
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
affects expression |
ISO |
diethyl malate affects the expression of CYP2J9 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Dapk2 |
death-associated protein kinase 2 |
affects expression |
ISO |
diethyl malate affects the expression of DAPK2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:71,822,107...71,941,941
Ensembl chr 8:71,822,129...71,941,910
|
|
G |
Ddx58 |
DEXD/H-box helicase 58 |
affects expression |
ISO |
diethyl malate affects the expression of DDX58 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
affects expression |
ISO |
diethyl malate affects the expression of DHRS3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
affects expression |
ISO |
diethyl malate affects the expression of DHX58 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:88,599,722...88,611,562
Ensembl chr10:88,599,680...88,611,105
|
|
G |
Edar |
ectodysplasin-A receptor |
affects expression |
ISO |
diethyl malate affects the expression of EDAR mRNA |
CTD |
PMID:24814887 |
|
NCBI chr20:28,179,132...28,263,092
Ensembl chr20:28,179,140...28,263,037
|
|
G |
Ednra |
endothelin receptor type A |
affects expression |
ISO |
diethyl malate affects the expression of EDNRA mRNA |
CTD |
PMID:24814887 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
affects expression |
ISO |
diethyl malate affects the expression of EPAS1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Epha7 |
Eph receptor A7 |
affects expression |
ISO |
diethyl malate affects the expression of EPHA7 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:43,602,744...43,761,198
Ensembl chr 5:43,603,043...43,757,549
|
|
G |
Ephb2 |
Eph receptor B2 |
affects expression |
ISO |
diethyl malate affects the expression of EPHB2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:155,024,478...155,143,539
Ensembl chr 5:155,022,493...155,204,456
|
|
G |
Ephb6 |
Eph receptor B6 |
affects expression |
ISO |
diethyl malate affects the expression of EPHB6 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 4:70,903,253...70,918,514
Ensembl chr 4:70,903,253...70,918,514
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
affects expression |
ISO |
diethyl malate affects the expression of FGF10 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions affects expression |
ISO |
S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of FGF18 mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr10:18,047,109...18,082,290
Ensembl chr10:18,047,109...18,063,391
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
affects expression |
ISO |
diethyl malate affects the expression of FGFR2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fst |
follistatin |
affects expression |
ISO |
diethyl malate affects the expression of FST mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
Fzd2 |
frizzled class receptor 2 |
affects expression |
ISO |
diethyl malate affects the expression of FZD2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:90,550,147...90,552,057
Ensembl chr10:90,550,147...90,552,057
|
|
G |
Fzd7 |
frizzled class receptor 7 |
affects expression |
ISO |
diethyl malate affects the expression of FZD7 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:66,305,731...66,308,550
Ensembl chr 9:66,305,731...66,308,550
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects expression |
ISO |
diethyl malate affects the expression of GCLC mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions affects expression |
ISO |
S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of GCLM mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Ggt6 |
gamma-glutamyl transferase 6 |
affects expression |
ISO |
diethyl malate affects the expression of GGT6 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:58,995,253...58,998,431
Ensembl chr10:58,995,556...58,998,033
|
|
G |
Gli2 |
GLI family zinc finger 2 |
affects expression |
ISO |
diethyl malate affects the expression of GLI2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
affects expression |
ISO |
diethyl malate affects the expression of GNAO1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr19:11,513,201...11,669,578
Ensembl chr19:11,513,201...11,669,578
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects expression |
ISO |
diethyl malate affects the expression of GNG7 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:11,565,740...11,629,519
Ensembl chr 7:11,582,984...11,628,929
|
|
G |
Gsr |
glutathione-disulfide reductase |
affects expression |
ISO |
diethyl malate affects the expression of GSR mRNA |
CTD |
PMID:24814887 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gss |
glutathione synthetase |
multiple interactions affects expression |
ISO |
S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of GSS mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
affects expression multiple interactions |
ISO |
diethyl malate affects the expression of GSTA3 mRNA S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of GSTA3 mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions affects expression |
ISO |
S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of GSTA1 mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
affects expression |
ISO |
diethyl malate affects the expression of GUCY1A1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
affects expression |
ISO |
diethyl malate affects the expression of GUCY1B1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
affects expression |
ISO |
diethyl malate affects the expression of HCK mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:148,579,917...148,623,026
Ensembl chr 3:148,579,920...148,623,033
|
|
G |
Hgf |
hepatocyte growth factor |
affects expression |
ISO |
diethyl malate affects the expression of HGF mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression |
ISO |
diethyl malate affects the expression of IGF1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il15 |
interleukin 15 |
affects expression |
ISO |
diethyl malate affects the expression of IL15 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr19:23,542,606...23,624,366
Ensembl chr19:23,542,889...23,554,594
|
|
G |
Il18 |
interleukin 18 |
affects expression |
ISO |
diethyl malate affects the expression of IL18 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Irag1 |
inositol 1,4,5-triphosphate receptor associated 1 |
affects expression |
ISO |
diethyl malate affects the expression of IRAG1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:175,681,960...175,804,737
Ensembl chr 1:175,681,960...175,796,040
|
|
G |
Irf7 |
interferon regulatory factor 7 |
affects expression |
ISO |
diethyl malate affects the expression of IRF7 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:214,249,388...214,252,909
Ensembl chr 1:214,248,837...214,252,456
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
affects expression |
ISO |
diethyl malate affects the expression of ISG15 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:173,624,862...173,629,124
Ensembl chr 5:173,624,310...173,626,248
|
|
G |
Itga11 |
integrin subunit alpha 11 |
affects expression |
ISO |
diethyl malate affects the expression of ITGA11 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:67,566,874...67,683,973
Ensembl chr 8:67,615,635...67,683,973
|
|
G |
Itga3 |
integrin subunit alpha 3 |
affects expression |
ISO |
diethyl malate affects the expression of ITGA3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
|
|
G |
Kcnmb4 |
potassium calcium-activated channel subfamily M regulatory beta subunit 4 |
affects expression |
ISO |
diethyl malate affects the expression of KCNMB4 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:59,461,808...59,514,759
Ensembl chr 7:59,461,799...59,514,939
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects expression |
ISO |
diethyl malate affects the expression of LAMA1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:115,916,907...116,042,123
Ensembl chr 9:115,916,907...116,042,123
|
|
G |
Lama4 |
laminin subunit alpha 4 |
affects expression |
ISO |
diethyl malate affects the expression of LAMA4 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr20:44,060,715...44,201,966
Ensembl chr20:44,060,731...44,209,614
|
|
G |
LOC100909797 |
RT1 class I histocompatibility antigen, AA alpha chain-like |
affects expression |
ISO |
diethyl malate affects the expression of H2-M3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr20:3,242,236...3,253,995
Ensembl chr20:3,242,470...3,249,189
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects phosphorylation multiple interactions |
ISO |
diethyl malate affects the phosphorylation of MAPK1 protein S-ethyl glutathione inhibits the reaction [diethyl malate affects the phosphorylation of MAPK1 protein] |
CTD |
PMID:24814887 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation multiple interactions |
ISO |
diethyl malate affects the phosphorylation of MAPK3 protein S-ethyl glutathione inhibits the reaction [diethyl malate affects the phosphorylation of MAPK3 protein] |
CTD |
PMID:24814887 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Myl9 |
myosin light chain 9 |
affects expression |
ISO |
diethyl malate affects the expression of MYL9 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:152,857,573...152,863,961
Ensembl chr 3:152,857,592...152,863,960
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
affects expression |
ISO |
diethyl malate affects the expression of ODC1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
affects expression multiple interactions |
ISO |
diethyl malate affects the expression of PDGFB mRNA S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of PDGFB mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfd |
platelet derived growth factor D |
affects expression |
ISO |
diethyl malate affects the expression of PDGFD mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:4,441,010...4,666,754
Ensembl chr 8:4,440,876...4,669,014
|
|
G |
Pf4 |
platelet factor 4 |
affects expression |
ISO |
diethyl malate affects the expression of PF4 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
affects expression |
ISO |
diethyl malate affects the expression of PIK3IP1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr14:83,559,397...83,572,481
Ensembl chr14:83,560,541...83,572,473
|
|
G |
Plxnc1 |
plexin C1 |
affects expression |
ISO |
diethyl malate affects the expression of PLXNC1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:35,848,083...36,000,969
Ensembl chr 7:35,850,398...36,000,906
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
affects expression |
ISO |
diethyl malate affects the expression of PRKG1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:248,982,039...250,300,952
|
|
G |
Ptgis |
prostaglandin I2 synthase |
affects expression |
ISO |
diethyl malate affects the expression of PTGIS mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:163,950,746...163,986,129
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
affects expression |
ISO |
diethyl malate affects the expression of RAMP2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr10:89,166,170...89,168,962
Ensembl chr10:89,166,890...89,168,965
|
|
G |
Rgs3 |
regulator of G-protein signaling 3 |
affects expression |
ISO |
diethyl malate affects the expression of RGS3 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:78,429,017...78,567,281
Ensembl chr 5:78,428,669...78,567,288
|
|
G |
Runx1t1 |
RUNX1 partner transcriptional co-repressor 1 |
affects expression |
ISO |
diethyl malate affects the expression of RUNX1T1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:27,284,921...27,440,802
Ensembl chr 5:27,312,928...27,442,841
|
|
G |
Sema3b |
semaphorin 3B |
affects expression |
ISO |
diethyl malate affects the expression of SEMA3B mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 8:116,353,791...116,362,655
Ensembl chr 8:116,354,073...116,361,343
|
|
G |
Sema4g |
semaphorin 4G |
affects expression |
ISO |
diethyl malate affects the expression of SEMA4G mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:264,738,935...264,753,399
Ensembl chr 1:264,741,911...264,753,397
|
|
G |
Sema5a |
semaphorin 5A |
affects expression |
ISO |
diethyl malate affects the expression of SEMA5A mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 2:85,377,318...85,808,970
Ensembl chr 2:85,377,318...85,808,970
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
affects expression |
ISO |
diethyl malate affects the expression of STAT1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
affects expression multiple interactions |
ISO |
diethyl malate affects the expression of TGFB2 mRNA S-ethyl glutathione inhibits the reaction [diethyl malate affects the expression of TGFB2 mRNA] |
CTD |
PMID:24814887 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Thbs1 |
thrombospondin 1 |
affects expression |
ISO |
diethyl malate affects the expression of THBS1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Thbs2 |
thrombospondin 2 |
affects expression |
ISO |
diethyl malate affects the expression of THBS2 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:56,653,929...56,683,571
Ensembl chr 1:56,653,938...56,683,731
|
|
G |
Tnc |
tenascin C |
affects expression |
ISO |
diethyl malate affects the expression of TNC mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
affects expression |
ISO |
diethyl malate affects the expression of TNFRSF11B mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnnt1 |
troponin T1, slow skeletal type |
affects expression |
ISO |
diethyl malate affects the expression of TNNT1 mRNA |
CTD |
PMID:24814887 |
|
NCBI chr 1:72,889,270...72,899,629
Ensembl chr 1:72,889,270...72,899,659
|
|
G |
Tslp |
thymic stromal lymphopoietin |
affects expression |
ISO |
diethyl malate affects the expression of TSLP mRNA |
CTD |
PMID:24814887 |
|
NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Mycophenolic Acid promotes the reaction [Esomeprazole results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:25929522 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of CCL2 mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases activity multiple interactions |
ISO |
eupatilin results in increased activity of CYP3A4 protein [[eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam; [eupatilin results in increased activity of CYP3A4 protein] which results in increased metabolism of Midazolam |
CTD |
PMID:31756459 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL1B mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:21565208 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of NOS2 protein] |
CTD |
PMID:21565208 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 mRNA]; eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] |
CTD |
PMID:21565208 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of RELA protein] |
CTD |
PMID:21565208 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
eupatilin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA] |
CTD |
PMID:21565208 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [ADCYAP1 protein affects the secretion of Acids] |
CTD |
PMID:20388963 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in increased expression of AGT protein] |
CTD |
PMID:27645307 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases activity |
ISO |
Famotidine results in decreased activity of BRAF protein |
CTD |
PMID:20823850 |
|
NCBI chr 4:67,389,331...67,520,549
Ensembl chr 4:67,396,192...67,520,356
|
|
G |
Ca12 |
carbonic anhydrase 12 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA12 protein |
CTD |
PMID:30344913 |
|
NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
|
|
G |
Ca6 |
carbonic anhydrase 6 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA6 protein |
CTD |
PMID:30344913 |
|
NCBI chr 5:167,226,246...167,244,786
Ensembl chr 5:167,226,246...167,244,786
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA2 protein |
CTD |
PMID:30344913 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Car7 |
carbonic anhydrase 7 |
multiple interactions |
ISO |
Famotidine binds to and results in decreased activity of CA7 protein |
CTD |
PMID:30344913 |
|
NCBI chr19:636,545...645,935
Ensembl chr19:636,545...645,937
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of CAT protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in decreased activity of CAT protein]] |
CTD |
PMID:18726076 PMID:19034656 PMID:19497431 PMID:25926722 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein]] |
CTD |
PMID:12538815 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased expression of CTNNB1 mRNA] Famotidine results in increased expression of CTNNB1 mRNA |
CTD |
PMID:31563592 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Famotidine results in increased expression of CXCL1 protein |
CTD |
PMID:12023551 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole] |
CTD |
PMID:15963082 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Famotidine co-treated with Sucralfate] results in increased expression of FGF2 mRNA |
CTD |
PMID:17717918 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
Famotidine results in increased expression of FGF21 protein |
CTD |
PMID:8774986 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA] |
CTD |
PMID:9187264 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gabra3 |
gamma-aminobutyric acid type A receptor subunit alpha 3 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr X:152,414,332...152,642,607
Ensembl chr X:152,414,615...152,642,531
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:27,973,694...28,193,072
Ensembl chr10:27,973,681...28,187,565
|
|
G |
Gabrg1 |
gamma-aminobutyric acid type A receptor subunit gamma 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG1 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG1 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr14:39,964,502...40,051,306
Ensembl chr14:39,964,588...40,049,354
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]; Famotidine inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA3 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15363660 |
|
NCBI chr10:27,090,913...27,179,786
Ensembl chr10:27,092,827...27,179,900
|
|
G |
Gast |
gastrin |
affects expression increases expression |
ISO EXP |
Famotidine affects the expression of GAST protein Famotidine results in increased expression of GAST protein |
CTD |
PMID:12503773 PMID:17652263 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
EXP |
Famotidine inhibits the reaction [GHRL protein results in increased secretion of Acids] |
CTD |
PMID:16838121 |
|
NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dizocilpine Maleate results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Famotidine inhibits the reaction [Dizocilpine Maleate results in increased expression of GSK3B mRNA] |
CTD |
PMID:31563592 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions decreases activity increases expression |
ISO EXP |
[Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Metformin; Famotidine binds to and results in decreased activity of HRH2 protein; Famotidine inhibits the reaction [[Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA]; Famotidine inhibits the reaction [[Histamine binds to and results in increased activity of HRH2 protein] which results in increased expression of FOS mRNA] Famotidine results in decreased activity of HRH2 protein [Famotidine binds to and results in decreased activity of HRH2 protein] which affects the susceptibility to Histamine Famotidine results in increased expression of HRH2 protein |
CTD |
PMID:9187264 PMID:9681472 PMID:12832840 PMID:15961859 PMID:16632449 PMID:21276809 |
|
NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression multiple interactions |
EXP |
Famotidine results in decreased expression of HSPA1A protein Zinc Compounds analog inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Famotidine results in decreased expression of HSPA1A protein] |
CTD |
PMID:16945336 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:12538815 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]] Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:19277450 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]] |
CTD |
PMID:11752121 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]] |
CTD |
PMID:11752121 PMID:12364868 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]] |
CTD |
PMID:11752121 PMID:12364868 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Cimetidine results in increased expression of IL18 protein]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in decreased expression of IL10 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of [IL12A protein binds to IL12B protein]]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of ICAM1 protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of IFNG protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]] |
CTD |
PMID:11752121 PMID:12364868 PMID:16723495 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
[Famotidine co-treated with Sucralfate] results in decreased expression of IL1B mRNA Famotidine inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of IL1B mRNA] |
CTD |
PMID:17717918 PMID:27474069 PMID:27645307 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]] |
CTD |
PMID:19277450 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]] |
CTD |
PMID:19277450 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of IL6 protein] |
CTD |
PMID:17603938 PMID:27474069 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17656145 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17656145 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; Famotidine inhibits the reaction [Histamine results in increased secretion of MMP1 protein] |
CTD |
PMID:17656145 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased expression of MMP9 mRNA]; Famotidine inhibits the reaction [Ethanol results in increased secretion of and results in increased activity of MMP9 protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of MMP9 protein] |
CTD |
PMID:17603938 PMID:22257724 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases expression |
ISO EXP |
Famotidine inhibits the reaction [Acids results in increased activity of MPO protein] Famotidine results in increased expression of MPO protein Famotidine inhibits the reaction [Ethanol results in increased activity of MPO protein]; Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]; Famotidine promotes the reaction [Chlorpheniramine results in decreased activity of MPO protein]; Quercetin promotes the reaction [Famotidine inhibits the reaction [Indomethacin results in increased activity of MPO protein]] |
CTD |
PMID:12023551 PMID:16091555 PMID:16437673 PMID:17603938 PMID:18726076 PMID:19034656 PMID:19497431 PMID:20723003 PMID:22257724 PMID:25926722 PMID:27474069 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Famotidine results in decreased expression of NPPB protein |
CTD |
PMID:30310171 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
[Pyrilamine co-treated with Famotidine co-treated with ciproxifan] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; [Pyrilamine co-treated with Famotidine] inhibits the reaction [Histamine results in increased expression of NTF3 protein]; Famotidine inhibits the reaction [Histamine results in increased expression of NTF3 protein] |
CTD |
PMID:21276809 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Famotidine co-treated with Indomethacin] promotes the reaction [Acetic Acid results in increased expression of PCNA protein]; Famotidine promotes the reaction [Acetic Acid results in increased expression of PCNA protein] |
CTD |
PMID:18853145 PMID:19251492 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression |
EXP |
Famotidine results in decreased expression of PPP3CA protein |
CTD |
PMID:30310171 |
|
NCBI chr 2:241,909,332...242,186,861
Ensembl chr 2:241,909,832...242,184,854
|
|
G |
Prdx3 |
peroxiredoxin 3 |
increases expression |
EXP |
Famotidine results in increased expression of PRDX3 protein |
CTD |
PMID:30310171 |
|
NCBI chr 1:282,238,774...282,251,193
Ensembl chr 1:282,238,773...282,251,257
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Famotidine results in increased expression of PRL protein |
CTD |
PMID:8104296 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in increased expression of PTGS1 mRNA] |
CTD |
PMID:27645307 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Indomethacin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27645307 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Famotidine inhibits the reaction [Ethanol results in increased expression of RELA protein] |
CTD |
PMID:27474069 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
affects expression |
ISO |
Famotidine affects the expression of HLA-DMB mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,945,383...3,952,838
Ensembl chr20:5,227,045...5,234,290
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
affects expression |
ISO |
Famotidine affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
Heparin promotes the reaction [[Famotidine co-treated with Lipopolysaccharides] results in increased expression of SERPINE1 protein] |
CTD |
PMID:16401727 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc19a3 |
solute carrier family 19 member 3 |
multiple interactions increases uptake |
ISO |
Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Famotidine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] SLC19A3 protein results in increased uptake of Famotidine |
CTD |
PMID:26528626 |
|
NCBI chr 9:88,762,775...88,828,553
Ensembl chr 9:88,764,073...88,816,898
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases uptake affects transport |
ISO EXP |
Famotidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein results in increased uptake of Famotidine SLC22A1 protein affects the transport of Famotidine |
CTD |
PMID:16006492 PMID:16141367 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake multiple interactions |
ISO EXP |
SLC22A2 protein results in increased uptake of Famotidine Famotidine inhibits the reaction [SLC22A2 protein affects the transport of Tetraethylammonium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:15496291 PMID:16006492 PMID:16141367 PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions decreases activity |
ISO |
Famotidine inhibits the reaction [SLC22A3 protein affects the transport of 1-Methyl-4-phenylpyridinium]; Famotidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Famotidine results in decreased activity of SLC22A3 protein |
CTD |
PMID:16141367 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions increases uptake |
ISO EXP |
estrone sulfate inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Famotidine inhibits the reaction [SLC22A8 protein affects the transport of estrone sulfate]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of Cimetidine]; Penicillin G inhibits the reaction [SLC22A8 protein results in increased uptake of Famotidine]; Probenecid inhibits the reaction [SLC22A8 protein affects the transport of Famotidine]; Probenecid promotes the reaction [SLC22A8 protein results in increased uptake of Famotidine] Famotidine inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:15100168 PMID:15319347 PMID:15496291 PMID:16006492 |
|
NCBI chr 1:224,799,444...224,818,482
Ensembl chr 1:224,800,252...224,818,482
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
Famotidine inhibits the reaction [Acids affects the localization of TACR1 protein] |
CTD |
PMID:16091555 |
|
NCBI chr 4:113,247,236...113,416,139
Ensembl chr 4:113,247,795...113,414,504
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO EXP |
Famotidine inhibits the reaction [Histamine inhibits the reaction [IL18 protein results in increased expression of TNF protein]]; Famotidine inhibits the reaction [Histamine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Famotidine results in increased secretion of TNF protein Famotidine inhibits the reaction [Dimaprit inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein]] Famotidine inhibits the reaction [Ethanol results in increased expression of TNF protein]; Famotidine inhibits the reaction [Ethanol results in increased secretion of TNF protein]; Famotidine inhibits the reaction [Indomethacin results in increased expression of TNF mRNA] |
CTD |
PMID:11752121 PMID:12538815 PMID:17603938 PMID:17698507 PMID:19277450 PMID:27474069 PMID:27645307 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP1A2 |
CTD |
PMID:18347083 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP3A4 |
CTD |
PMID:18347083 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
F2 |
coagulation factor II |
affects expression |
ISO |
hydrocortisone hemisuccinate affects the expression of F2 protein |
CTD |
PMID:12542493 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
Il18 |
interleukin 18 |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL18 protein |
CTD |
PMID:20421217 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL1B protein |
CTD |
PMID:20421217 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL6 protein |
CTD |
PMID:20421217 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of TNF protein |
CTD |
PMID:20421217 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Lansoprazole results in increased expression of ABCA1 protein Lansoprazole results in increased expression of ABCA1 mRNA; Lansoprazole results in increased expression of ABCA1 protein |
CTD |
PMID:20060385 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1 affects the susceptibility to Lansoprazole |
CTD |
PMID:19238367 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
ISO |
Lansoprazole results in increased expression of APOE mRNA; Lansoprazole results in increased expression of APOE protein |
CTD |
PMID:20060385 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Aqp4 |
aquaporin 4 |
increases expression |
ISO |
Lansoprazole results in increased expression of AQP4 mRNA; Lansoprazole results in increased expression of AQP4 protein |
CTD |
PMID:20437101 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in decreased expression of BCL2 mRNA] |
CTD |
PMID:28412091 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C1QA mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C1QC mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C4BPA mRNA |
CTD |
PMID:25626140 |
|
NCBI chr13:47,342,090...47,377,580
Ensembl chr13:47,342,079...47,377,703
|
|
G |
C4bpb |
complement component 4 binding protein, beta |
decreases expression |
EXP |
Lansoprazole results in decreased expression of C4BPB mRNA |
CTD |
PMID:25626140 |
|
NCBI chr13:47,387,173...47,398,115
Ensembl chr13:47,387,173...47,397,890
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Lansoprazole inhibits the reaction [Demecolcine results in increased activity of CASP3 protein] Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of CASP3 mRNA]; Lansoprazole inhibits the reaction [Ethanol results in increased expression of CASP3 protein] |
CTD |
PMID:12530016 PMID:28412091 PMID:29339218 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased activity of CAT protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of CAT protein] |
CTD |
PMID:18726076 PMID:29339218 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cfi |
complement factor I |
decreases expression |
EXP |
Lansoprazole results in decreased expression of CFI mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 2:235,264,149...235,305,779
Ensembl chr 2:235,264,219...235,305,781
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
decreases expression multiple interactions |
EXP |
Lansoprazole results in decreased expression of CXCL1 mRNA; Lansoprazole results in decreased expression of CXCL1 protein Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA]; Lansoprazole inhibits the reaction [Indomethacin results in increased expression of CXCL1 protein] |
CTD |
PMID:15334676 PMID:16328016 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression |
ISO EXP |
Lansoprazole results in increased activity of CYP1A1 promoter Lansoprazole results in increased expression of CYP1A1 mRNA; Lansoprazole results in increased expression of CYP1A1 protein |
CTD |
PMID:8169844 PMID:8647108 PMID:8900397 PMID:9041675 PMID:9152597 PMID:9860486 PMID:10859152 PMID:12623754 PMID:14550749 PMID:18502397 PMID:25626140 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO EXP |
Lansoprazole results in increased expression of CYP1A2 mRNA; Lansoprazole results in increased expression of CYP1A2 protein |
CTD |
PMID:8169844 PMID:9152597 PMID:9744552 PMID:12623754 PMID:14550749 PMID:25626140 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
Lansoprazole results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12623754 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP2B1 protein |
CTD |
PMID:9152597 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP2B2 protein |
CTD |
PMID:9152597 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases hydroxylation |
ISO |
CYP2C18 protein results in increased hydroxylation of Lansoprazole |
CTD |
PMID:7870052 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
affects response to substance increases expression decreases activity increases hydroxylation affects metabolic processing increases metabolic processing decreases metabolic processing multiple interactions |
ISO EXP |
CYP2C19 gene affects the susceptibility to Lansoprazole; CYP2C19 gene polymorphism affects the susceptibility to Lansoprazole Lansoprazole results in increased expression of CYP2C6V1 mRNA; Lansoprazole results in increased expression of CYP2C6V1 protein Lansoprazole results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased hydroxylation of Lansoprazole CYP2C19 protein affects the metabolism of Lansoprazole CYP2C19 protein results in increased metabolism of Lansoprazole; Lansoprazole results in increased metabolism of CYP2C19 protein CYP2C19 gene polymorphism results in decreased metabolism of Lansoprazole CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]; Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole]; Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] |
CTD |
PMID:8627562 PMID:8930576 PMID:9152597 PMID:9272410 PMID:11829200 PMID:11929404 PMID:12975331 PMID:14550749 PMID:15010519 PMID:15258107 PMID:15285851 PMID:15963082 PMID:17377957 PMID:19814645 PMID:21212520 PMID:21795468 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects metabolic processing increases hydroxylation |
ISO |
CYP2C8 protein affects the metabolism of Lansoprazole CYP2C8 protein results in increased hydroxylation of Lansoprazole |
CTD |
PMID:7870052 PMID:8627562 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases metabolic processing increases expression increases hydroxylation affects metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of Lansoprazole Lansoprazole results in increased expression of CYP3A4 mRNA; Lansoprazole results in increased expression of CYP3A4 protein CYP3A4 protein results in increased hydroxylation of Lansoprazole CYP3A4 protein affects the metabolism of Lansoprazole |
CTD |
PMID:7870052 PMID:8627562 PMID:8930576 PMID:9744552 PMID:10859152 PMID:11829200 PMID:12975331 PMID:15010519 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] |
CTD |
PMID:17377957 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
Lansoprazole results in increased expression of CYP4A1 protein |
CTD |
PMID:9152597 |
|
NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
Lansoprazole results in increased expression of EGFR protein |
CTD |
PMID:9881512 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FAS protein] |
CTD |
PMID:29339218 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in increased expression of FASLG protein] |
CTD |
PMID:29339218 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
ISO |
Lansoprazole results in decreased expression of FGF2 protein |
CTD |
PMID:9881512 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
Lansoprazole results in increased expression of FGF21 protein |
CTD |
PMID:8774986 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Gast |
gastrin |
increases expression |
ISO EXP |
Lansoprazole results in increased expression of GAST protein |
CTD |
PMID:7750667 PMID:8792694 PMID:11680587 PMID:11975934 PMID:12189558 PMID:12438555 PMID:20095383 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Lansoprazole inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
ISO |
Lansoprazole results in increased expression of HAMP mRNA |
CTD |
PMID:31669099 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; Lansoprazole results in increased activity of and results in increased expression of HMOX1 protein Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Lansoprazole results in increased expression of HMOX1 protein] Lansoprazole results in increased expression of HMOX1 mRNA; Lansoprazole results in increased expression of HMOX1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lansoprazole results in increased activity of HMOX1 promoter] |
CTD |
PMID:16712795 PMID:19628634 PMID:19764090 PMID:28412091 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression |
ISO |
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 PMID:19232345 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein] |
CTD |
PMID:29339218 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Lansoprazole results in decreased expression of IL1B mRNA Lansoprazole inhibits the reaction [Ethanol results in increased expression of IL1B protein] |
CTD |
PMID:16932910 PMID:29339218 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO EXP |
Lansoprazole results in decreased expression of IL6 mRNA Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of IL6 mRNA] |
CTD |
PMID:16932910 PMID:28412091 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases oxidation |
EXP |
Lansoprazole results in increased oxidation of KEAP1 protein |
CTD |
PMID:19628634 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions increases expression |
EXP |
Lansoprazole inhibits the reaction [LHB protein results in increased abundance of Testosterone] Lansoprazole results in increased expression of LHB protein |
CTD |
PMID:7589908 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
EXP |
Lansoprazole results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19628634 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
EXP |
Lansoprazole results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19628634 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
affects binding |
ISO |
Lansoprazole binds to MAPT protein alternative form |
CTD |
PMID:20110603 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in increased expression of MPO protein]; Lansoprazole inhibits the reaction [Indomethacin results in increased activity of MPO protein] |
CTD |
PMID:17151854 PMID:17895592 PMID:18726076 PMID:24337826 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases expression increases phosphorylation |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of NFE2L2 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 mRNA]; NFE2L2 mRNA affects the reaction [Lansoprazole results in increased expression of HMOX1 protein] Lansoprazole results in increased expression of NFE2L2 mRNA Lansoprazole results in increased phosphorylation of NFE2L2 protein |
CTD |
PMID:19628634 PMID:28412091 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:29339218 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1H2 protein |
CTD |
PMID:20060385 |
|
NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1H3 protein |
CTD |
PMID:20060385 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Lansoprazole results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Phospho1 |
phosphoethanolamine/phosphocholine phosphatase 1 |
decreases activity |
ISO |
Lansoprazole results in decreased activity of PHOSPHO1 protein |
CTD |
PMID:17227223 |
|
NCBI chr10:83,635,557...83,643,862
Ensembl chr10:83,636,518...83,643,859
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
ISO |
Lansoprazole results in increased expression of POMC protein |
CTD |
PMID:16524691 |
|
NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
AG-041R inhibits the reaction [Lansoprazole results in increased expression of PTGS2 protein] |
CTD |
PMID:12438555 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Ethanol results in decreased expression of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:29339218 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Retsat |
retinol saturase |
decreases expression |
EXP |
Lansoprazole results in decreased expression of RETSAT mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 4:100,465,365...100,474,128
Ensembl chr 4:100,465,170...100,474,301
|
|
G |
Serping1 |
serpin family G member 1 |
decreases expression |
EXP |
Lansoprazole results in decreased expression of SERPING1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 3:72,161,230...72,171,109
Ensembl chr 3:72,161,189...72,171,078
|
|
G |
Shh |
sonic hedgehog signaling molecule |
decreases expression |
ISO |
Lansoprazole results in decreased expression of SHH mRNA |
CTD |
PMID:20437101 |
|
NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Lansoprazole inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
ISO |
Lansoprazole results in increased expression of TGFA protein |
CTD |
PMID:9881512 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Lansoprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] Lansoprazole inhibits the reaction [Ethanol results in increased expression of TNF protein] Lansoprazole results in decreased expression of TNF mRNA |
CTD |
PMID:16932910 PMID:19232345 PMID:29339218 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Lansoprazole inhibits the reaction [Diatrizoate Meglumine results in increased expression of TP53 mRNA] |
CTD |
PMID:28412091 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
EXP |
Lansoprazole results in increased expression of UGT1A1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
increases expression |
EXP |
Lansoprazole results in increased expression of UGT2B1 mRNA |
CTD |
PMID:25626140 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions decreases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in decreased abundance of malic acid] |
CTD |
PMID:27469509 |
|
NCBI chr 1:141,874,354...141,893,674
Ensembl chr 1:141,866,283...141,893,705
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
increases expression |
ISO |
malic acid deficiency results in increased expression of MDH1 mRNA |
CTD |
PMID:26811028 |
|
NCBI chr14:106,378,349...106,393,642
Ensembl chr14:106,378,942...106,393,670
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
[[NR1H4 protein co-treated with Dietary Fats] results in increased susceptibility to caffeic acid phenethyl ester] which results in increased abundance of malic acid |
CTD |
PMID:28223344 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
malic acid results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions increases hydrolysis |
EXP |
Dexamethasone promotes the reaction [CES2 protein results in increased hydrolysis of Methylprednisolone Hemisuccinate] |
CTD |
PMID:15794950 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
EXP |
Misoprostol inhibits the reaction [ADCYAP1 protein results in increased secretion of Histamine] |
CTD |
PMID:11164953 |
|
NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Misoprostol inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:18602972 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Misoprostol inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein] |
CTD |
PMID:18602972 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Misoprostol inhibits the reaction [Cisplatin results in decreased expression of CAT protein] |
CTD |
PMID:21458517 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
EXP |
Misoprostol inhibits the reaction [(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride binds to and results in increased activity of CHRM1 protein] |
CTD |
PMID:2459756 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Gast |
gastrin |
multiple interactions decreases activity |
EXP |
Misoprostol inhibits the reaction [GAST protein results in increased secretion of Histamine] Misoprostol results in decreased activity of GAST protein |
CTD |
PMID:2459756 PMID:11164953 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10] |
CTD |
PMID:19273625 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10] |
CTD |
PMID:19273625 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions increases expression |
ISO |
Misoprostol inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10] Misoprostol results in increased expression of IL23A mRNA |
CTD |
PMID:19273625 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions |
ISO |
[L-335677 binds to and results in decreased activity of PTGER1 protein] inhibits the reaction [Misoprostol results in increased susceptibility to Formaldehyde] |
CTD |
PMID:16360148 |
|
NCBI chr19:24,799,422...24,803,373
Ensembl chr19:24,800,072...24,803,373
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
[6-isopropoxy-9-oxoxanthene-2-carboxylic acid binds to and results in decreased activity of PTGER2 protein] inhibits the reaction [Misoprostol results in increased susceptibility to Formaldehyde] |
CTD |
PMID:16360148 |
|
NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
ISO |
[L-826266 binds to and results in decreased activity of PTGER3 protein] inhibits the reaction [Misoprostol results in decreased susceptibility to Formaldehyde] |
CTD |
PMID:16360148 |
|
NCBI chr 2:263,895,093...263,979,682
Ensembl chr 2:263,895,241...263,979,698
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide inhibits the reaction [Misoprostol results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Misoprostol results in increased expression of PTGS2 protein] |
CTD |
PMID:12428691 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Misoprostol promotes the reaction [Kallidin results in increased secretion of TAC1 protein] |
CTD |
PMID:16039053 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Misoprostol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] |
CTD |
PMID:9298541 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
[alpha-ketoisocaproic acid co-treated with monomethyl succinate] inhibits the reaction [Palmitates results in decreased expression of SLC2A4 mRNA] |
CTD |
PMID:21802492 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
monomethyl succinate inhibits the reaction [bis((2-oxindol-3-ylimino)-2-(2-aminoethyl)pyridine-N,N')copper(II) results in increased expression of TP53 protein] |
CTD |
PMID:21548882 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases expression |
ISO |
Nizatidine results in increased expression of CALCA protein |
CTD |
PMID:12495560 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases expression |
ISO |
Nizatidine results in increased expression of TAC1 protein |
CTD |
PMID:12495560 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Omeprazole results in increased expression of ABCA1 mRNA |
CTD |
PMID:20060385 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Omeprazole results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects expression multiple interactions |
EXP ISO |
Omeprazole affects the expression of ABCB1A mRNA Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1 protein] Omeprazole promotes the reaction [Cisplatin results in increased expression of ABCB1A protein] |
CTD |
PMID:19483382 PMID:30452898 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases expression |
ISO |
Omeprazole results in decreased expression of ABCB4 mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Omeprazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:19118567 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects expression |
EXP |
Omeprazole affects the expression of ABCC6 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
Omeprazole results in increased expression of ABCG2 mRNA alternative form; Omeprazole results in increased expression of ABCG2 protein Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow] |
CTD |
PMID:20804740 PMID:31348918 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects expression |
EXP |
Omeprazole affects the expression of ABCG5 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
affects expression |
EXP |
Omeprazole affects the expression of ABHD1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 6:26,787,807...26,792,795
Ensembl chr 6:26,784,058...26,792,808
|
|
G |
Abhd14b |
abhydrolase domain containing 14b |
affects expression |
EXP |
Omeprazole affects the expression of ABHD14B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 8:115,149,638...115,154,556
Ensembl chr 8:115,150,514...115,154,550
|
|
G |
Abhd17a |
abhydrolase domain containing 17A, depalmitoylase |
affects expression |
EXP |
Omeprazole affects the expression of ABHD17A mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:11,992,543...12,000,978
Ensembl chr 7:11,992,543...11,998,973
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
affects expression |
EXP |
Omeprazole affects the expression of ACACA mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
affects expression |
EXP |
Omeprazole affects the expression of ACADL mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 9:73,833,368...73,871,857
Ensembl chr 9:73,833,388...73,871,888
|
|
G |
Aco1 |
aconitase 1 |
affects expression |
EXP |
Omeprazole affects the expression of ACO1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
affects expression |
EXP |
Omeprazole affects the expression of ACO2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
affects expression |
EXP |
Omeprazole affects the expression of ACOT12 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:20,857,056...20,901,656
Ensembl chr 2:20,857,202...20,901,659
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects expression |
EXP |
Omeprazole affects the expression of ACOT4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 6:107,517,668...107,522,952
Ensembl chr 6:107,517,668...107,522,952
|
|
G |
Adam15 |
ADAM metallopeptidase domain 15 |
affects expression |
EXP |
Omeprazole affects the expression of ADAM15 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:188,661,831...188,672,337
Ensembl chr 2:188,661,699...188,672,247
|
|
G |
Add1 |
adducin 1 |
affects expression |
EXP |
Omeprazole affects the expression of ADD1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr14:81,367,466...81,426,610
Ensembl chr14:81,367,468...81,426,496
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
decreases expression |
ISO |
Omeprazole results in decreased expression of ADH1C mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
affects expression |
EXP |
Omeprazole affects the expression of ADH4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:243,702,035...243,720,063
Ensembl chr 2:243,700,784...243,740,899
|
|
G |
Adtrp |
androgen-dependent TFPI-regulating protein |
affects expression |
EXP |
Omeprazole affects the expression of ADTRP mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:22,619,913...22,688,296
Ensembl chr17:22,619,891...22,688,307
|
|
G |
Afm |
afamin |
affects expression |
EXP |
Omeprazole affects the expression of AFM mRNA |
CTD |
PMID:19483382 |
|
NCBI chr14:19,078,678...19,132,212
Ensembl chr14:19,078,680...19,132,208
|
|
G |
Agt |
angiotensinogen |
affects expression |
EXP |
Omeprazole affects the expression of AGT mRNA |
CTD |
PMID:19483382 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
affects expression |
EXP |
Omeprazole affects the expression of AGTR1A mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:35,907,102...35,958,136
Ensembl chr17:35,907,108...35,958,077
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases activity increases activity increases expression decreases expression affects localization increases response to substance |
ISO EXP |
AG-879 inhibits the reaction [Omeprazole results in increased activity of AHR protein]; AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of AHR mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein]; Omeprazole binds to and results in increased activity of AHR protein; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; omeprazole sulfide inhibits the reaction [Omeprazole results in increased activity of AHR protein]; Puromycin inhibits the reaction [Omeprazole results in increased expression of AHR protein] Omeprazole results in decreased activity of AHR protein Omeprazole affects the localization of AHR protein AHR protein results in increased susceptibility to Omeprazole [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Omeprazole affects the localization of [ARNT protein co-treated with AHR protein] |
CTD |
PMID:9139728 PMID:9395520 PMID:14742684 PMID:16109480 PMID:20171196 PMID:21703235 PMID:21861773 PMID:21924250 PMID:22687989 PMID:23850985 PMID:25797602 PMID:25826687 PMID:26187274 PMID:26272953 PMID:31669099 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
affects expression |
EXP |
Omeprazole affects the expression of AKR1A1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:135,482,068...135,498,693
Ensembl chr 5:135,482,068...135,498,822
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
affects expression |
EXP |
Omeprazole affects the expression of AKR7A2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:157,759,448...157,768,473
Ensembl chr 5:157,759,416...157,768,471
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
affects expression multiple interactions |
EXP |
Omeprazole affects the expression of AKR7A3 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA |
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 5:157,801,120...157,813,756
Ensembl chr 5:157,801,163...157,813,756
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects expression multiple interactions |
EXP |
Omeprazole affects the expression of ALDH1A1 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:19483382 PMID:22687989 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
Omeprazole results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
affects expression |
EXP |
Omeprazole affects the expression of ALDH2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression |
ISO |
Omeprazole results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:12040753 |
|
NCBI chr10:47,490,168...47,499,855
Ensembl chr10:47,490,153...47,499,876
|
|
G |
Alkbh7 |
alkB homolog 7 |
affects expression |
EXP |
Omeprazole affects the expression of ALKBH7 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 9:10,045,375...10,047,507
Ensembl chr 9:10,045,375...10,047,507
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
affects expression |
EXP |
Omeprazole affects the expression of AP2M1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:84,041,184...84,047,542
Ensembl chr11:84,041,184...84,047,546
|
|
G |
Apcs |
amyloid P component, serum |
affects expression |
EXP |
Omeprazole affects the expression of APCS mRNA |
CTD |
PMID:19483382 |
|
NCBI chr13:91,426,621...91,427,417
Ensembl chr13:91,426,479...91,427,575
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
EXP |
Omeprazole affects the expression of APOA4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 8:50,536,983...50,539,371
Ensembl chr 8:50,537,009...50,539,376
|
|
G |
Apoh |
apolipoprotein H |
affects expression |
EXP |
Omeprazole affects the expression of APOH mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:96,640,013...96,653,939
Ensembl chr10:96,639,924...96,653,938
|
|
G |
Apool |
apolipoprotein O-like |
affects expression |
EXP |
Omeprazole affects the expression of APOOL mRNA |
CTD |
PMID:19483382 |
|
NCBI chr X:83,678,269...83,750,550
Ensembl chr X:83,678,339...83,750,549
|
|
G |
Arg1 |
arginase 1 |
affects expression |
EXP |
Omeprazole affects the expression of ARG1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of ARL6IP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:187,770,160...187,779,675
Ensembl chr 1:187,770,160...187,779,675
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions affects localization |
ISO EXP |
Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter] Omeprazole affects the localization of ARNT protein Omeprazole affects the localization of [ARNT protein co-treated with AHR protein] |
CTD |
PMID:9395520 PMID:21703235 PMID:25826687 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Asgr2 |
asialoglycoprotein receptor 2 |
affects expression |
EXP |
Omeprazole affects the expression of ASGR2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:56,710,446...56,723,608
Ensembl chr10:56,710,464...56,723,611
|
|
G |
Atf5 |
activating transcription factor 5 |
affects expression |
EXP |
Omeprazole affects the expression of ATF5 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atp5f1e |
ATP synthase F1 subunit epsilon |
affects expression |
EXP |
Omeprazole affects the expression of ATP5F1E mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:172,563,105...172,566,007
Ensembl chr 3:172,563,105...172,566,010
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
affects expression |
EXP |
Omeprazole affects the expression of ATP6AP2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr X:11,137,889...11,164,854
Ensembl chr X:11,136,939...11,164,915
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
affects expression |
EXP |
Omeprazole affects the expression of ATP6V1A mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:61,531,386...61,584,634
Ensembl chr11:61,531,416...61,584,634
|
|
G |
Atp6v1f |
ATPase H+ transporting V1 subunit F |
affects expression |
EXP |
Omeprazole affects the expression of ATP6V1F mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 4:56,744,563...56,747,657
Ensembl chr 4:56,744,561...56,747,656
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
Omeprazole inhibits the reaction [ATP7A protein results in increased activity of TYR protein] Omeprazole inhibits the reaction [Copper affects the localization of ATP7A protein]; Omeprazole inhibits the reaction [cupric chloride affects the localization of ATP7A protein] |
CTD |
PMID:25337692 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
affects expression |
EXP |
Omeprazole affects the expression of BAAT mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:64,768,397...64,777,368
Ensembl chr 5:64,768,401...64,777,368
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Omeprazole inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:30452898 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Omeprazole inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:30452898 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
affects expression |
EXP |
Omeprazole affects the expression of BCL6B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:56,834,363...56,840,058
Ensembl chr10:56,834,364...56,839,437
|
|
G |
Bmf |
Bcl2 modifying factor |
affects expression |
EXP |
Omeprazole affects the expression of BMF mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084
|
|
G |
Bmx |
BMX non-receptor tyrosine kinase |
multiple interactions |
ISO |
BMX mRNA affects the reaction [Omeprazole results in increased activity of AHR protein] |
CTD |
PMID:21861773 |
|
NCBI chr X:31,976,231...32,046,326
Ensembl chr X:31,984,612...32,045,448
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
affects expression |
EXP |
Omeprazole affects the expression of BNIP3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Btf3 |
basic transcription factor 3 |
affects expression |
EXP |
Omeprazole affects the expression of BTF3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:28,417,316...28,424,436
Ensembl chr 2:28,417,579...28,423,762
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
EXP |
Omeprazole results in decreased expression of C1QA mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:155,261,254...155,264,101
Ensembl chr 5:155,261,250...155,264,143
|
|
G |
C1qbp |
complement C1q binding protein |
affects expression |
EXP |
Omeprazole affects the expression of C1QBP mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:57,613,876...57,618,527
Ensembl chr10:57,613,879...57,618,527
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP |
Omeprazole results in decreased expression of C1QC mRNA |
CTD |
PMID:25626140 |
|
NCBI chr 5:155,255,013...155,258,631
Ensembl chr 5:155,255,005...155,258,392
|
|
G |
C1s |
complement C1s |
affects expression |
EXP |
Omeprazole affects the expression of C1S mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 4:157,143,592...157,155,592
Ensembl chr 4:157,143,592...157,155,609
|
|
G |
C2cd2 |
C2 calcium-dependent domain containing 2 |
affects expression |
EXP |
Omeprazole affects the expression of C2CD2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:38,354,746...38,420,133
Ensembl chr11:38,357,424...38,420,119
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
affects expression decreases expression |
EXP |
Omeprazole affects the expression of C4BPA mRNA Omeprazole results in decreased expression of C4BPA mRNA |
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr13:47,342,090...47,377,580
Ensembl chr13:47,342,079...47,377,703
|
|
G |
C4bpb |
complement component 4 binding protein, beta |
decreases expression |
EXP |
Omeprazole results in decreased expression of C4BPB mRNA |
CTD |
PMID:25626140 |
|
NCBI chr13:47,387,173...47,398,115
Ensembl chr13:47,387,173...47,397,890
|
|
G |
C7 |
complement C7 |
affects expression |
EXP |
Omeprazole affects the expression of C7 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:54,707,621...54,781,624
Ensembl chr 2:54,709,138...54,777,729
|
|
G |
C8b |
complement C8 beta chain |
affects expression |
EXP |
Omeprazole affects the expression of C8B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:124,298,269...124,338,055
Ensembl chr 5:124,300,477...124,338,053
|
|
G |
Ca3 |
carbonic anhydrase 3 |
affects expression |
EXP |
Omeprazole affects the expression of CAR3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Cadps2 |
calcium dependent secretion activator 2 |
affects expression |
EXP |
Omeprazole affects the expression of CADPS2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 4:50,326,447...50,861,161
Ensembl chr 4:50,326,442...50,860,756
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of CAPRIN1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:93,701,830...93,789,580
Ensembl chr 3:93,702,487...93,789,617
|
|
G |
Car2 |
carbonic anhydrase 2 |
affects expression |
EXP |
Omeprazole affects the expression of CA2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions affects expression increases cleavage |
ISO EXP |
Omeprazole analog results in increased activity of CASP3 protein; Omeprazole results in increased activity of CASP3 protein Omeprazole inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] Omeprazole inhibits the reaction [Ethanol results in increased activity of CASP3 protein]; Omeprazole inhibits the reaction [Ethanol results in increased expression of CASP3 mRNA]; Omeprazole inhibits the reaction [Indomethacin results in increased activity of CASP3 protein] Omeprazole affects the expression of CASP3 mRNA Omeprazole results in increased cleavage of CASP3 protein |
CTD |
PMID:15461867 PMID:18336733 PMID:19251492 PMID:19483382 PMID:25637687 PMID:30452898 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
Omeprazole analog results in increased cleavage of CASP8 protein |
CTD |
PMID:18336733 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
increases activity |
EXP |
Omeprazole results in increased activity of CAT protein |
CTD |
PMID:18547560 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cbr1 |
carbonyl reductase 1 |
affects expression |
EXP |
Omeprazole affects the expression of CBR1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:33,813,041...33,815,418
Ensembl chr11:33,845,463...33,847,793
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3 |
CTD |
PMID:17704804 |
|
NCBI chr 1:170,262,218...170,272,298
Ensembl chr 1:170,262,156...170,272,298
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Omeprazole results in decreased expression of CCND1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Omeprazole results in increased expression of CDKN1A protein |
CTD |
PMID:27358234 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
affects expression |
EXP |
Omeprazole affects the expression of CDO1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr18:40,702,027...40,716,901
Ensembl chr18:40,701,984...40,716,686
|
|
G |
Cept1 |
choline/ethanolamine phosphotransferase 1 |
affects expression |
EXP |
Omeprazole affects the expression of CEPT1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:209,118,140...209,162,071
Ensembl chr 2:209,118,922...209,160,653
|
|
G |
Ces2h |
carboxylesterase 2H |
affects expression |
EXP |
Omeprazole affects the expression of CES2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cfi |
complement factor I |
affects expression decreases expression |
EXP |
Omeprazole affects the expression of CFI mRNA Omeprazole results in decreased expression of CFI mRNA |
CTD |
PMID:19483382 PMID:25626140 |
|
NCBI chr 2:235,264,149...235,305,779
Ensembl chr 2:235,264,219...235,305,781
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects metabolic processing |
ISO |
CFTR protein affects the metabolism of Omeprazole |
CTD |
PMID:15319328 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Chp1 |
calcineurin-like EF-hand protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of CHP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:111,354,506...111,389,998
Ensembl chr 3:111,354,506...111,389,989
|
|
G |
Cisd1 |
CDGSH iron sulfur domain 1 |
affects expression |
EXP |
Omeprazole affects the expression of CISD1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr20:18,493,538...18,506,923
Ensembl chr20:18,493,538...18,506,912
|
|
G |
Clcn4 |
chloride voltage-gated channel 4 |
affects expression |
EXP |
Omeprazole affects the expression of CLCN4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr X:25,016,177...25,082,563
Ensembl chr X:25,016,401...25,080,410
|
|
G |
Clpp |
caseinolytic mitochondrial matrix peptidase proteolytic subunit |
affects expression |
EXP |
Omeprazole affects the expression of CLPP mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 9:10,048,715...10,056,068
Ensembl chr 9:10,048,886...10,054,359
|
|
G |
Clptm1l |
CLPTM1-like |
affects expression |
EXP |
Omeprazole affects the expression of CLPTM1L mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:32,281,207...32,297,196
Ensembl chr 1:32,281,207...32,297,190
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
affects expression |
EXP |
Omeprazole affects the expression of CMBL mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:84,645,084...84,666,836
Ensembl chr 2:84,645,084...84,666,835
|
|
G |
Cmpk1 |
cytidine/uridine monophosphate kinase 1 |
affects expression |
EXP |
Omeprazole affects the expression of CMPK1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:133,759,722...133,786,452
Ensembl chr 5:133,759,735...133,786,452
|
|
G |
Copg1 |
COPI coat complex subunit gamma 1 |
affects expression |
EXP |
Omeprazole affects the expression of COPG1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 4:119,815,041...119,840,997
Ensembl chr 4:119,815,139...119,864,114
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
affects expression |
EXP |
Omeprazole affects the expression of COPS4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr14:10,718,863...10,749,134
Ensembl chr14:10,718,844...10,749,120
|
|
G |
Coq3 |
coenzyme Q3 methyltransferase |
affects expression |
EXP |
Omeprazole affects the expression of COQ3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:36,024,673...36,056,664
Ensembl chr 5:36,024,649...36,056,669
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
affects expression |
EXP |
Omeprazole affects the expression of COX4I1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225
|
|
G |
Cpn1 |
carboxypeptidase N subunit 1 |
affects expression |
EXP |
Omeprazole affects the expression of CPN1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:263,733,887...263,762,758
Ensembl chr 1:263,733,519...263,762,785
|
|
G |
Cpq |
carboxypeptidase Q |
affects expression |
EXP |
Omeprazole affects the expression of CPQ mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:71,709,174...72,167,413
Ensembl chr 7:71,709,157...72,167,417
|
|
G |
Crem |
cAMP responsive element modulator |
affects expression |
EXP |
Omeprazole affects the expression of CREM mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Csnk2b |
casein kinase 2 beta |
affects expression |
EXP |
Omeprazole affects the expression of CSNK2B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr20:5,108,692...5,113,675
Ensembl chr20:5,106,890...5,113,112
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of CSRP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr13:52,553,843...52,575,054
Ensembl chr13:52,553,775...52,575,051
|
|
G |
Ctnna1 |
catenin alpha 1 |
affects expression |
EXP |
Omeprazole affects the expression of CTNNA1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr18:27,923,229...28,055,972
Ensembl chr18:27,923,572...28,055,960
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein] |
CTD |
PMID:20165931 |
|
NCBI chr 1:215,541,570...215,553,446
Ensembl chr 1:215,541,542...215,553,451
|
|
G |
Ctse |
cathepsin E |
decreases expression |
EXP |
Omeprazole results in decreased expression of CTSE |
CTD |
PMID:7575556 |
|
NCBI chr13:48,426,833...48,449,493
Ensembl chr13:48,426,820...48,449,490
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression multiple interactions |
ISO |
Omeprazole results in decreased expression of CXCR4 mRNA AHR protein affects the reaction [Omeprazole results in decreased expression of CXCR4 mRNA] |
CTD |
PMID:25826687 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity multiple interactions decreases activity increases expression |
ISO EXP |
Omeprazole results in increased activity of CYP1A1 promoter Omeprazole inhibits the reaction [Oxygen results in increased expression of CYP1A1 protein]; Omeprazole promotes the reaction [Oxygen results in decreased expression of CYP1A1 mRNA] Omeprazole results in decreased activity of CYP1A1 protein Omeprazole results in increased expression of CYP1A1 mRNA; Omeprazole results in increased expression of CYP1A1 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A1 mRNA; AHR protein promotes the reaction [Omeprazole results in increased expression of CYP1A1 protein]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; daidzein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; Genistein inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased activity of CYP1A1 protein]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; lavendustin A inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Staurosporine inhibits the reaction [Omeprazole results in increased expression of CYP1A1 protein]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA] AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein mutant form inhibits the reaction [Omeprazole results in increased expression of CYP1A1 mRNA]; AHR protein promotes the reaction [Omeprazole results in decreased expression of CYP1A1 mRNA]; Omeprazole promotes the reaction [AHR protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1A1 promoter] |
CTD |
PMID:8647108 PMID:8900397 PMID:9041675 PMID:9139728 PMID:9152597 PMID:9395520 PMID:9860486 PMID:10103034 PMID:10859152 PMID:11454723 PMID:11849738 PMID:12040753 PMID:12623754 PMID:12841937 PMID:14742684 PMID:14987951 PMID:15681896 PMID:15860653 PMID:17202759 PMID:17954527 PMID:18420780 PMID:18502397 PMID:19118567 PMID:20171196 PMID:21666223 PMID:21703235 PMID:21784029 PMID:22687989 PMID:25626140 PMID:25826687 PMID:26272953 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases activity increases expression decreases activity multiple interactions |
ISO EXP |
Omeprazole results in increased activity of CYP1A2 promoter; Omeprazole results in increased activity of CYP1A2 protein Omeprazole results in increased expression of CYP1A2 mRNA; Omeprazole results in increased expression of CYP1A2 protein Omeprazole results in decreased activity of CYP1A2 protein [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of CYP1A2 mRNA [Omeprazole results in increased expression of CYP1A2 protein] which results in decreased alkylation of Phenacetin; AHR protein affects the susceptibility to [Omeprazole results in increased expression of CYP1A2 mRNA]; Omeprazole results in increased expression of and results in increased activity of CYP1A2 protein |
CTD |
PMID:9152597 PMID:9744552 PMID:12040753 PMID:12623754 PMID:12841937 PMID:15681896 PMID:15802389 PMID:16035375 PMID:17954527 PMID:18332078 PMID:18420780 PMID:18502397 PMID:19118567 PMID:19230594 PMID:20171196 PMID:21784029 PMID:21924250 PMID:22524704 PMID:22687989 PMID:23274770 PMID:23850985 PMID:24752503 PMID:25626140 PMID:26204831 PMID:27794450 PMID:31863871 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions affects expression decreases activity increases expression |
ISO |
Omeprazole promotes the reaction [AHR protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [ARNT protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter]; Omeprazole promotes the reaction [NCOA1 protein binds to CYP1B1 promoter] Omeprazole affects the expression of CYP1B1 mRNA Omeprazole results in decreased activity of CYP1B1 protein Omeprazole results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12040753 PMID:12623754 PMID:18420780 PMID:21703235 PMID:25826687 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
affects expression |
EXP |
Omeprazole affects the expression of CYP2A1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression decreases activity |
EXP ISO |
Omeprazole results in increased expression of CYP2B1 mRNA; Omeprazole results in increased expression of CYP2B1 protein Omeprazole results in decreased activity of CYP2B10 protein |
CTD |
PMID:9152597 PMID:18420780 PMID:19118567 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression affects expression |
EXP |
Omeprazole results in increased expression of CYP2B2 protein Omeprazole affects the expression of CYP2B2 mRNA |
CTD |
PMID:9152597 PMID:19483382 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects expression increases expression increases activity |
EXP ISO |
Omeprazole affects the expression of CYP2B3 mRNA Omeprazole results in increased expression of CYP2B6 mRNA Omeprazole results in increased activity of CYP2B6 protein |
CTD |
PMID:17954527 PMID:19118567 PMID:19483382 PMID:22524704 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases metabolic processing decreases activity multiple interactions increases hydroxylation increases metabolic processing affects metabolic processing |
ISO |
CYP2C19 gene alternative form results in decreased metabolism of Omeprazole Omeprazole results in decreased activity of CYP2C19 protein [5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole; Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin]; Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of auriculasin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of Clopidogrel] CYP2C19 protein results in increased hydroxylation of Omeprazole CYP2C19 protein results in increased metabolism of Omeprazole CYP2C19 protein affects the metabolism of Omeprazole |
CTD |
PMID:8930576 PMID:9600717 PMID:11752104 PMID:12464242 PMID:12467917 PMID:12485723 PMID:12637241 PMID:14586384 PMID:15258107 PMID:15286053 PMID:15306208 PMID:15626586 PMID:16035375 PMID:17565714 PMID:17702393 PMID:18511451 PMID:18520598 PMID:19812348 PMID:20573087 PMID:21277363 PMID:21795468 PMID:21915887 PMID:22634058 PMID:26599973 PMID:31515991 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
affects expression |
EXP |
Omeprazole affects the expression of CYP2D3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:123,634,400...123,638,757
Ensembl chr 7:123,625,590...123,638,765
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects expression decreases activity |
EXP ISO |
Omeprazole affects the expression of CYP2D4 mRNA Omeprazole results in decreased activity of CYP2D6 protein |
CTD |
PMID:18420780 PMID:19483382 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
Omeprazole results in increased expression of and results in increased activity of CYP2E1 protein |
CTD |
PMID:15802389 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
affects expression |
EXP |
Omeprazole affects the expression of CYP2F4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
affects expression |
EXP |
Omeprazole affects the expression of CYP2J4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:119,546,458...119,564,843
Ensembl chr 5:119,546,461...119,564,846
|
|
G |
Cyp2t1 |
cytochrome P450, family 2, subfamily t, polypeptide 1 |
affects expression |
EXP |
Omeprazole affects the expression of CYP2T1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:83,965,370...83,969,466
Ensembl chr 1:83,965,608...83,969,559
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects expression increases expression |
EXP |
Omeprazole affects the expression of CYP3A23-3A1 mRNA Omeprazole results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression increases metabolic processing multiple interactions affects metabolic processing |
ISO |
Omeprazole results in increased expression of CYP3A4 mRNA; Omeprazole results in increased expression of CYP3A4 protein CYP3A4 protein results in increased metabolism of Omeprazole [Omeprazole results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein affects the reaction [Omeprazole results in increased expression of CYP3A4 mRNA]; Omeprazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]; Omeprazole results in increased expression of and results in increased activity of CYP3A4 protein CYP3A4 protein affects the metabolism of Omeprazole |
CTD |
PMID:7870052 PMID:8930576 PMID:9744552 PMID:12235278 PMID:12485723 PMID:12695340 PMID:15286053 PMID:15466163 PMID:15626586 PMID:15802389 PMID:17041008 PMID:17565714 PMID:17954527 PMID:19118567 PMID:19299527 PMID:22634058 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects expression increases expression |
EXP ISO |
Omeprazole affects the expression of CYP3A9 mRNA Omeprazole results in increased expression of CYP3A5 mRNA |
CTD |
PMID:19118567 PMID:19483382 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4a8 |
cytochrome P450, family 4, subfamily a, polypeptide 8 |
affects expression |
EXP |
Omeprazole affects the expression of CYP4A8 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:133,978,953...134,008,255
Ensembl chr 5:133,978,954...134,008,255
|
|
G |
Cyp4f6 |
cytochrome P450, family 4, subfamily f, polypeptide 6 |
affects expression |
EXP |
Omeprazole affects the expression of CYP4F6 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:15,198,950...15,225,547
Ensembl chr 7:15,198,940...15,225,410
|
|
G |
Dbi |
diazepam binding inhibitor, acyl-CoA binding protein |
affects expression |
EXP |
Omeprazole affects the expression of DBI mRNA |
CTD |
PMID:19483382 |
|
NCBI chr13:36,147,667...36,156,076
Ensembl chr13:36,117,119...36,174,908
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
affects expression |
EXP |
Omeprazole affects the expression of DCAF11 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr15:34,233,840...34,244,512
Ensembl chr15:34,234,193...34,244,504
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
affects expression |
EXP |
Omeprazole affects the expression of DCXR mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:109,906,119...109,909,696
Ensembl chr10:109,906,815...109,909,715
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Omeprazole results in increased expression of DDIT3 protein |
CTD |
PMID:27358234 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
affects expression |
EXP |
Omeprazole affects the expression of DECR1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:29,573,893...29,601,731
Ensembl chr 5:29,573,898...29,601,748
|
|
G |
Dexi |
Dexi homolog |
affects expression |
EXP |
Omeprazole affects the expression of DEXI mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:5,199,226...5,211,913
Ensembl chr10:5,199,226...5,211,913
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
affects expression |
EXP |
Omeprazole affects the expression of DGAT1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:117,566,363...117,576,735
Ensembl chr 7:117,566,368...117,576,737
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
affects expression |
EXP |
Omeprazole affects the expression of DHCR24 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dhrs4 |
dehydrogenase/reductase 4 |
affects expression |
EXP |
Omeprazole affects the expression of DHRS4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr15:34,155,043...34,167,073
Ensembl chr15:34,155,504...34,167,072
|
|
G |
Dhrs7b |
dehydrogenase/reductase 7B |
affects expression |
EXP |
Omeprazole affects the expression of DHRS7B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:47,065,755...47,111,089
Ensembl chr10:47,065,850...47,111,101
|
|
G |
Dhx16 |
DEAH-box helicase 16 |
affects expression |
EXP |
Omeprazole affects the expression of DHX16 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr20:3,368,971...3,386,087
Ensembl chr20:3,367,150...3,386,106
|
|
G |
Dmac2l |
distal membrane arm assembly component 2 like |
affects expression |
EXP |
Omeprazole affects the expression of DMAC2L mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 6:92,057,782...92,076,022
Ensembl chr 6:92,057,807...92,076,021
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
affects expression |
EXP |
Omeprazole affects the expression of DNAJC3 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
affects expression |
EXP |
Omeprazole affects the expression of DPP4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
affects expression |
EXP |
Omeprazole affects the expression of DPYD mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Ears2 |
glutamyl-tRNA synthetase 2, mitochondrial |
affects expression |
EXP |
Omeprazole affects the expression of EARS2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:191,997,512...192,025,350
Ensembl chr 1:191,997,512...192,025,350
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
affects expression |
EXP |
Omeprazole affects the expression of ECHS1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
affects expression |
EXP |
Omeprazole affects the expression of ECI1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:13,797,573...13,810,918
Ensembl chr10:13,797,562...13,810,913
|
|
G |
Eci2 |
enoyl-CoA delta isomerase 2 |
affects expression |
EXP |
Omeprazole affects the expression of ECI2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:30,556,926...30,573,324
Ensembl chr17:30,556,884...30,639,040
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
affects expression |
EXP |
Omeprazole affects the expression of EEF1G mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:225,163,391...225,173,997
Ensembl chr 1:225,163,391...225,173,995
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Omeprazole promotes the reaction [Indomethacin results in increased expression of EGF protein] |
CTD |
PMID:18431645 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
affects expression |
EXP |
Omeprazole affects the expression of EHHADH mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:82,945,104...82,978,364
Ensembl chr11:82,945,104...82,978,364
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
affects expression |
EXP |
Omeprazole affects the expression of EIF4A2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:81,373,047...81,379,680
Ensembl chr11:81,373,048...81,379,871
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of EIF4EBP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
affects expression |
EXP |
Omeprazole affects the expression of EIF4H mRNA |
CTD |
PMID:19483382 |
|
NCBI chr12:25,093,119...25,109,805
Ensembl chr12:25,093,149...25,109,799
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
affects expression |
EXP |
Omeprazole affects the expression of ENC1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:28,049,217...28,061,023
Ensembl chr 2:28,049,217...28,061,029
|
|
G |
Eno1 |
enolase 1 |
affects expression |
EXP |
Omeprazole affects the expression of ENO1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Enpep |
glutamyl aminopeptidase |
affects expression |
EXP |
Omeprazole affects the expression of ENPEP mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:233,667,253...233,743,866
Ensembl chr 2:233,667,254...233,743,866
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
affects expression |
EXP |
Omeprazole affects the expression of ENPP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:21,748,201...21,813,205
Ensembl chr 1:21,748,261...21,813,371
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
Omeprazole promotes the reaction [EP300 protein binds to CYP1A1 promoter]; Omeprazole promotes the reaction [EP300 protein binds to CYP1B1 promoter] |
CTD |
PMID:21703235 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Epcam |
epithelial cell adhesion molecule |
affects expression |
EXP |
Omeprazole affects the expression of EPCAM mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
affects expression |
EXP |
Omeprazole affects the expression of ERP29 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr12:40,619,377...40,625,884
Ensembl chr12:40,619,377...40,625,883
|
|
G |
Esd |
esterase D |
affects expression |
EXP |
Omeprazole affects the expression of ESD mRNA |
CTD |
PMID:19483382 |
|
NCBI chr15:56,756,848...56,776,348
Ensembl chr15:56,756,661...56,776,348
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
affects expression |
EXP |
Omeprazole affects the expression of ETFB mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:98,472,776...98,486,940
Ensembl chr 1:98,472,745...98,486,976
|
|
G |
Faah |
fatty acid amide hydrolase |
affects expression |
EXP |
Omeprazole affects the expression of FAAH mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Fads2 |
fatty acid desaturase 2 |
affects expression |
EXP |
Omeprazole affects the expression of FADS2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
affects expression |
EXP |
Omeprazole affects the expression of FBP1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:396,175...417,480
Ensembl chr17:396,180...417,480
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects expression |
EXP |
Omeprazole affects the expression of FDFT1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fdps |
farnesyl diphosphate synthase |
affects expression |
EXP |
Omeprazole affects the expression of FDPS mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:188,403,595...188,413,219
Ensembl chr 2:188,392,858...188,413,219
|
|
G |
Fdx2 |
ferredoxin 2 |
affects expression |
EXP |
Omeprazole affects the expression of FDX2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 8:22,086,534...22,091,450
Ensembl chr 8:22,086,534...22,091,450
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
affects expression |
EXP |
Omeprazole affects the expression of FMO1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
|
|
G |
Gamt |
guanidinoacetate N-methyltransferase |
affects expression |
EXP |
Omeprazole affects the expression of GAMT mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:12,314,848...12,317,998
Ensembl chr 7:12,314,848...12,317,998
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
affects expression |
EXP |
Omeprazole affects the expression of GAPDH mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gast |
gastrin |
increases expression |
ISO EXP |
Omeprazole results in increased expression of GAST protein |
CTD |
PMID:11422300 PMID:12189558 PMID:12763636 PMID:15223672 PMID:16618411 PMID:17652263 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gbe1 |
1,4-alpha-glucan branching enzyme 1 |
affects expression |
EXP |
Omeprazole affects the expression of GBE1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:7,210,169...7,485,895
Ensembl chr11:7,210,209...7,485,890
|
|
G |
Gchfr |
GTP cyclohydrolase I feedback regulator |
affects expression |
EXP |
Omeprazole affects the expression of GCHFR mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 3:110,975,923...110,979,957
Ensembl chr 3:110,975,923...110,979,957
|
|
G |
Ggh |
gamma-glutamyl hydrolase |
affects expression |
EXP |
Omeprazole affects the expression of GGH mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:34,040,258...34,063,369
Ensembl chr 5:34,040,258...34,063,361
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GGT1 mRNA |
CTD |
PMID:22687989 |
|
NCBI chr20:14,019,723...14,045,781
Ensembl chr20:14,019,723...14,025,068
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
affects expression |
EXP |
Omeprazole affects the expression of GJB1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr X:71,272,030...71,279,973
Ensembl chr X:71,272,042...71,279,977
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
affects expression |
EXP |
Omeprazole affects the expression of GPLD1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr17:42,085,027...42,131,344
Ensembl chr17:42,085,028...42,127,678
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects expression |
EXP |
Omeprazole affects the expression of GPX1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GPX2 mRNA |
CTD |
PMID:22687989 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
affects expression |
EXP |
Omeprazole affects the expression of GPX4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Grina |
glutamate ionotropic receptor NMDA type subunit associated protein 1 |
affects expression |
EXP |
Omeprazole affects the expression of GRINA mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:117,304,742...117,307,916
Ensembl chr 7:117,304,742...117,307,916
|
|
G |
Grpel1 |
GrpE-like 1, mitochondrial |
affects expression |
EXP |
Omeprazole affects the expression of GRPEL1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr14:79,458,951...79,464,782
Ensembl chr14:79,458,963...79,464,770
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases expression multiple interactions |
EXP |
Omeprazole results in increased expression of GSTA5 mRNA [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of GSTA5 mRNA |
CTD |
PMID:17202759 PMID:22687989 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression |
EXP |
Omeprazole results in increased expression of GSTP1 mRNA |
CTD |
PMID:19118567 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects expression |
EXP |
Omeprazole affects the expression of GSTT1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gtf2h5 |
general transcription factor IIH subunit 5 |
affects expression |
EXP |
Omeprazole affects the expression of GTF2H5 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:46,978,345...46,985,032
Ensembl chr 1:46,978,458...46,985,032
|
|
G |
Gzma |
granzyme A |
affects expression |
EXP |
Omeprazole affects the expression of GZMA mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:44,968,846...44,981,436
Ensembl chr 2:44,968,765...44,981,458
|
|
G |
H3f3b |
H3.3 histone B |
affects expression |
EXP |
Omeprazole affects the expression of H3F3B mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:104,573,666...104,575,890
Ensembl chr10:104,573,664...104,575,890
|
|
G |
Hal |
histidine ammonia lyase |
affects expression |
EXP |
Omeprazole affects the expression of HAL mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:34,326,087...34,356,413
Ensembl chr 7:34,326,087...34,356,413
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression multiple interactions increases secretion |
ISO |
Omeprazole results in increased expression of HAMP mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Omeprazole results in increased expression of HAMP mRNA]; AHR protein affects the reaction [Omeprazole results in increased expression of HAMP mRNA] Omeprazole results in increased expression of HAMP mRNA; Omeprazole results in increased expression of HAMP protein Omeprazole results in increased secretion of HAMP protein |
CTD |
PMID:31669099 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hao2 |
hydroxyacid oxidase 2 |
affects expression |
EXP |
Omeprazole affects the expression of HAO2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:200,785,492...200,808,868
Ensembl chr 2:200,778,122...200,808,857
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
affects expression |
EXP |
Omeprazole affects the expression of HBA-A2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Hbb |
hemoglobin subunit beta |
affects expression |
EXP |
Omeprazole affects the expression of HBB mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hdc |
histidine decarboxylase |
affects expression increases stability increases expression multiple interactions |
EXP |
Omeprazole affects the expression of HDC mRNA Omeprazole results in increased stability of HDC protein Omeprazole results in increased expression of HDC mRNA Omeprazole results in increased expression of and results in increased activity of HDC protein |
CTD |
PMID:12763636 PMID:19483382 |
|
NCBI chr 3:119,057,524...119,075,599
Ensembl chr 3:119,057,517...119,075,619
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
affects expression |
EXP |
Omeprazole affects the expression of HGD mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:65,983,221...66,034,555
Ensembl chr11:65,983,221...66,034,573
|
|
G |
Hmgn1 |
high mobility group nucleosome binding domain 1 |
affects expression |
EXP |
Omeprazole affects the expression of HMGN1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr11:36,474,028...36,479,947
Ensembl chr11:36,474,840...36,479,868
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; Acetylcysteine promotes the reaction [Omeprazole results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [Omeprazole results in increased expression of HMOX1 protein]; Omeprazole results in increased expression of and results in increased activity of HMOX1 protein Omeprazole results in increased expression of HMOX1 mRNA; Omeprazole results in increased expression of HMOX1 protein |
CTD |
PMID:16712795 PMID:27725188 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
affects expression |
EXP |
Omeprazole affects the expression of HPRT1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr X:158,196,640...158,228,815
Ensembl chr X:158,197,149...158,228,749
|
|
G |
Hps5 |
HPS5, biogenesis of lysosomal organelles complex 2 subunit 2 |
affects expression |
EXP |
Omeprazole affects the expression of HPS5 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:102,810,114...102,849,430
Ensembl chr 1:102,776,082...102,849,430
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects expression |
EXP |
Omeprazole affects the expression of HSD17B4 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
affects expression |
EXP |
Omeprazole affects the expression of HSDL2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 5:76,812,881...76,848,853
Ensembl chr 5:76,812,931...76,848,101
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression multiple interactions |
EXP |
Omeprazole results in decreased expression of HSPA1A mRNA; Omeprazole results in decreased expression of HSPA1A protein Zinc Compounds analog inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein]; Zinc Sulfate inhibits the reaction [Omeprazole results in decreased expression of HSPA1A protein] |
CTD |
PMID:15223672 PMID:16945336 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
EXP |
Omeprazole inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA] |
CTD |
PMID:25637687 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
affects expression |
EXP |
Omeprazole affects the expression of HTRA1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[Omeprazole co-treated with CCKBR protein] results in increased expression of IER3 |
CTD |
PMID:17704804 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Omeprazole inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] |
CTD |
PMID:19232345 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression |
EXP |
Omeprazole affects the expression of IGF1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfals |
insulin-like growth factor binding protein, acid labile subunit |
affects expression |
EXP |
Omeprazole affects the expression of IGFALS mRNA |
CTD |
PMID:19483382 |
|
NCBI chr10:14,240,308...14,243,554
Ensembl chr10:14,240,219...14,243,597
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
affects expression |
EXP |
Omeprazole affects the expression of IGFBP2 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 9:80,118,029...80,144,804
Ensembl chr 9:80,118,029...80,144,789
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL10 protein] |
CTD |
PMID:26970604 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL1B protein] |
CTD |
PMID:32418911 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Omeprazole inhibits the reaction [Cisplatin results in increased expression of IL6 protein]; Omeprazole inhibits the reaction [Ethanol results in decreased expression of IL6 protein] |
CTD |
PMID:25637687 PMID:32418911 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Impa1 |
inositol monophosphatase 1 |
affects expression |
EXP |
Omeprazole affects the expression of IMPA1 mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 2:93,675,203...93,696,355
Ensembl chr 2:93,675,203...93,696,232
|
|
G |
Inhbe |
inhibin subunit beta E |
affects expression |
EXP |
Omeprazole affects the expression of INHBE mRNA |
CTD |
PMID:19483382 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075.. | |